Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Influenza

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 682 articles:
HTML format



Single Articles


    December 2022
  1. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Five Disease Outbreaks beyond Covid-19.
    N Engl J Med. 2022;387:e68.
    PubMed    


    November 2022
  2. ABERG M, Smed-Sorensen A, Thalin C
    Mucosal IgA against SARS-CoV-2 Omicron Infection. Reply.
    N Engl J Med. 2022;387:e55.
    PubMed    


  3. ZUO F, Marcotte H, Hammarstrom L, Pan-Hammarstrom Q, et al
    Mucosal IgA against SARS-CoV-2 Omicron Infection.
    N Engl J Med. 2022;387:e55.
    PubMed    


  4. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Making Choices about Covid-19.
    N Engl J Med. 2022;387:e64.
    PubMed    


  5. RUBIN EJ, Baden LR, Marks P, Morrissey S, et al
    Audio Interview: The FDA and Covid-19 Vaccines.
    N Engl J Med. 2022;387:e60.
    PubMed    


  6. GOLDEN MR, Wasserheit JN
    Monkeypox - A Sobering Sentinel for Pandemic Preparedness and Sexual Health System Capacity.
    N Engl J Med. 2022;387:1826-1829.
    PubMed    


  7. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Masking and Covid-19.
    N Engl J Med. 2022;387:e56.
    PubMed    


  8. VENKATARAMANI V, Winkler F
    Cognitive Deficits in Long Covid-19.
    N Engl J Med. 2022;387:1813-1815.
    PubMed    


  9. FRICCHIONE GL, Paul AB, Chemali Z, Kritzer MD, et al
    Case 34-2022: A 57-Year-Old Woman with Covid-19 and Delusions.
    N Engl J Med. 2022;387:1795-1803.
    PubMed    


  10. RAIFMAN J, Green T
    Universal Masking Policies in Schools and Mitigating the Inequitable Costs of Covid-19.
    N Engl J Med. 2022 Nov 9. doi: 10.1056/NEJMe2213556.
    PubMed    


  11. COWGER TL, Murray EJ, Clarke J, Bassett MT, et al
    Lifting Universal Masking in Schools - Covid-19 Incidence among Students and Staff.
    N Engl J Med. 2022 Nov 9. doi: 10.1056/NEJMoa2211029.
    PubMed     Abstract available


  12. CHESKES S, Verbeek PR, Drennan IR, McLeod SL, et al
    Defibrillation Strategies for Refractory Ventricular Fibrillation.
    N Engl J Med. 2022 Nov 6. doi: 10.1056/NEJMoa2207304.
    PubMed     Abstract available


  13. RUBIN EJ, Baden LR, Hardin CC, Morrissey S, et al
    Audio Interview: Caring for Hospitalized Patients with Covid-19.
    N Engl J Med. 2022;387:e51.
    PubMed    


  14. CHEMAITELLY H, AlMukdad S, Ayoub HH, Altarawneh HN, et al
    Covid-19 Vaccine Protection among Children and Adolescents in Qatar.
    N Engl J Med. 2022 Nov 2. doi: 10.1056/NEJMoa2210058.
    PubMed     Abstract available


    October 2022
  15. EMANUEL EJ, Upshur REG, Smith MJ
    What Covid Has Taught the World about Ethics.
    N Engl J Med. 2022;387:1542-1545.
    PubMed    


  16. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Assessing the Effect of Vaccination and Prior SARS-CoV-2 Infection.
    N Engl J Med. 2022;387:e50.
    PubMed    


  17. CHIN ET, Leidner D, Lamson L, Lucas K, et al
    Protection against Omicron from Vaccination and Previous Infection in a Prison System.
    N Engl J Med. 2022 Oct 26. doi: 10.1056/NEJMoa2207082.
    PubMed     Abstract available


  18. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Covid-19: Where Are We Heading?
    N Engl J Med. 2022;387:e47.
    PubMed    


  19. ANDERSON EJ, Creech CB, Berthaud V, Piramzadian A, et al
    Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age.
    N Engl J Med. 2022 Oct 19. doi: 10.1056/NEJMoa2209367.
    PubMed     Abstract available


  20. WITBERG G, Magen O, Hoss S, Talmor-Barkan Y, et al
    Myocarditis after BNT162b2 Vaccination in Israeli Adolescents.
    N Engl J Med. 2022 Oct 19. doi: 10.1056/NEJMc2207270.
    PubMed    


  21. HACHMANN NP, Miller J, Collier AY, Barouch DH, et al
    Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6.
    N Engl J Med. 2022 Oct 19. doi: 10.1056/NEJMc2212117.
    PubMed    


  22. RUBIN EJ, Baden LR, Neuzil KM, Morrissey S, et al
    Audio Interview: Developing New Covid-19 Vaccines.
    N Engl J Med. 2022;387:e44.
    PubMed    


  23. CHEMAITELLY H, Ayoub HH, Tang P, Hasan MR, et al
    Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2.
    N Engl J Med. 2022 Oct 12. doi: 10.1056/NEJMc2211055.
    PubMed    


  24. ALTARAWNEH HN, Chemaitelly H, Ayoub HH, Hasan MR, et al
    Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants.
    N Engl J Med. 2022 Oct 5. doi: 10.1056/NEJMc2209306.
    PubMed    


    September 2022
  25. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Assessing Bivalent Vaccines against Covid-19.
    N Engl J Med. 2022;387:e37.
    PubMed    


  26. TAKASHITA E, Yamayoshi S, Fukushi S, Suzuki T, et al
    Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75.
    N Engl J Med. 2022;387:1236-1238.
    PubMed    


  27. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Can Vaccines Prevent Transmission of Covid-19?
    N Engl J Med. 2022;387:e30.
    PubMed    


  28. THURNER L, Kessel C, Fadle N, Regitz E, et al
    IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination.
    N Engl J Med. 2022 Sep 21. doi: 10.1056/NEJMc2205667.
    PubMed    


  29. CHALKIAS S, Harper C, Vrbicky K, Walsh SR, et al
    A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
    N Engl J Med. 2022 Sep 16. doi: 10.1056/NEJMoa2208343.
    PubMed     Abstract available


  30. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Developing Mucosal Immunity to Covid-19.
    N Engl J Med. 2022;387:e29.
    PubMed    


  31. HAVERVALL S, Marking U, Svensson J, Greilert-Norin N, et al
    Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection.
    N Engl J Med. 2022 Sep 14. doi: 10.1056/NEJMc2209651.
    PubMed    


  32. COLLIE S, Nayager J, Bamford L, Bekker LG, et al
    Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa.
    N Engl J Med. 2022 Sep 14. doi: 10.1056/NEJMc2210093.
    PubMed    


  33. SHEN X, Chalkias S, Feng J, Chen X, et al
    Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination.
    N Engl J Med. 2022 Sep 9. doi: 10.1056/NEJMc2210648.
    PubMed    


  34. SULLIVAN DJ, Gebo KA, Hanley DF
    Convalescent Plasma for Covid-19. Reply.
    N Engl J Med. 2022;387:955-956.
    PubMed    


  35. PANETH N
    Convalescent Plasma for Covid-19.
    N Engl J Med. 2022;387:955.
    PubMed    


  36. JOYNER MJ, Pirofski LA
    Convalescent Plasma for Covid-19.
    N Engl J Med. 2022;387:955.
    PubMed    


  37. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Rolling Out New Covid-19 Vaccines.
    N Engl J Med. 2022;387:e26.
    PubMed    


  38. CHARNESS ME, Gupta K, Stack G, Strymish J, et al
    Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment.
    N Engl J Med. 2022 Sep 7. doi: 10.1056/NEJMc2206449.
    PubMed    


  39. ANDERSON AS, Caubel P, Rusnak JM
    Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19.
    N Engl J Med. 2022 Sep 7. doi: 10.1056/NEJMc2205944.
    PubMed    


  40. LIN DY, Gu Y, Xu Y, Zeng D, et al
    Effects of Vaccination and Previous Infection on Omicron Infections in Children.
    N Engl J Med. 2022 Sep 7. doi: 10.1056/NEJMc2209371.
    PubMed    


  41. QU P, Faraone JN, Evans JP, Zheng YM, et al
    Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants.
    N Engl J Med. 2022 Sep 7. doi: 10.1056/NEJMc2210546.
    PubMed    


  42. DUPONT SC, Galea S
    Science, Competing Values, and Trade-offs in Public Health - The Example of Covid-19 and Masking.
    N Engl J Med. 2022 Sep 3. doi: 10.1056/NEJMp2207670.
    PubMed    


  43. RUBIN EJ, Baden LR, Swaminathan S, Morrissey S, et al
    Audio Interview: Covid-19 and the WHO.
    N Engl J Med. 2022;387:e24.
    PubMed    


    August 2022
  44. BAROUCH DH
    Covid-19 Vaccines - Immunity, Variants, Boosters.
    N Engl J Med. 2022 Aug 31. doi: 10.1056/NEJMra2206573.
    PubMed    


  45. MALATO J, Ribeiro RM, Leite PP, Casaca P, et al
    Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants.
    N Engl J Med. 2022 Aug 31. doi: 10.1056/NEJMc2209479.
    PubMed    


  46. MACDONALD SM, Berv J
    Losing Contact - Covid-19, Telemedicine, and the Patient-Provider Relationship.
    N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMp2206471.
    PubMed    


  47. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Choosing an Antiviral to Treat Covid-19.
    N Engl J Med. 2022;387:e22.
    PubMed    


  48. ARBEL R, Wolff Sagy Y, Hoshen M, Battat E, et al
    Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge.
    N Engl J Med. 2022 Aug 24. doi: 10.1056/NEJMoa2204919.
    PubMed     Abstract available


  49. ABDOOL KARIM SS, Devnarain N
    Time to Stop Using Ineffective Covid-19 Drugs.
    N Engl J Med. 2022;387:654-655.
    PubMed    


  50. BRAMANTE CT, Huling JD, Tignanelli CJ, Buse JB, et al
    Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
    N Engl J Med. 2022;387:599-610.
    PubMed     Abstract available


  51. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Combating Covid-19 Today and Tomorrow.
    N Engl J Med. 2022;387:e17.
    PubMed    


  52. JOST TS
    Considering Race and Ethnicity in Covid Risk Assessments - Legal Concerns and Possible Solutions.
    N Engl J Med. 2022;387:481-483.
    PubMed    


  53. KOHANE I, Omenn GS
    Understanding Covid Vaccine Efficacy over Time - Bridging a Gap Between Public Health and Health Care.
    N Engl J Med. 2022 Aug 6. doi: 10.1056/NEJMp2201084.
    PubMed    


  54. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Updated Covid-19 Vaccines and a Look at Monkeypox.
    N Engl J Med. 2022;387:e16.
    PubMed    


  55. TAKASHITA E, Yamayoshi S, Simon V, van Bakel H, et al
    Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants.
    N Engl J Med. 2022;387:468-470.
    PubMed    


    July 2022
  56. RUBIN EJ, Baden LR, Currier JS, Morrissey S, et al
    Audio Interview: Reinventing the Research Infrastructure to Address Covid-19.
    N Engl J Med. 2022;387:e13.
    PubMed    


  57. RUBIN EJ, Baden LR, Jha A, Morrissey S, et al
    Audio Interview: A Look at the U.S. Government's Covid-19 Strategy.
    N Engl J Med. 2022;387:e11.
    PubMed    


  58. HAMMOND J, Bao W, Simon-Campos A
    Nirmatrelvir for Nonhospitalized Adults with Covid-19. Reply.
    N Engl J Med. 2022;387.
    PubMed    


  59. MORRIS AM, Lee TC
    Nirmatrelvir for Nonhospitalized Adults with Covid-19.
    N Engl J Med. 2022;387.
    PubMed    


  60. CHEN BS, Hung CH, Wei JC
    Nirmatrelvir for Nonhospitalized Adults with Covid-19.
    N Engl J Med. 2022;387.
    PubMed    


  61. TAN SHX, Cook AR, Heng D, Ong B, et al
    Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age.
    N Engl J Med. 2022 Jul 20. doi: 10.1056/NEJMoa2203209.
    PubMed     Abstract available


  62. MAIER HE, Balmaseda A, Saborio S, Ojeda S, et al
    Protection Associated with Previous SARS-CoV-2 Infection in Nicaragua.
    N Engl J Med. 2022 Jul 20. doi: 10.1056/NEJMc2203985.
    PubMed    


  63. RUBIN EJ, Baden LR, Marks P, Morrissey S, et al
    Audio Interview: Covid-19 Vaccines and the FDA.
    N Engl J Med. 2022;387:e10.
    PubMed    


  64. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Designing the Next Covid-19 Vaccine.
    N Engl J Med. 2022;387:e6.
    PubMed    


  65. ZHAO X, Zhang R, Qiao S, Wang X, et al
    Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines.
    N Engl J Med. 2022 Jul 6. doi: 10.1056/NEJMc2206900.
    PubMed    


    June 2022
  66. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: How Effective is Covid-19 Vaccination in Children?
    N Engl J Med. 2022;386:e78.
    PubMed    


  67. WAXMAN JG, Magen O, Hernan MA
    Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine. Reply.
    N Engl J Med. 2022;387.
    PubMed    


  68. TUMMINIA A, Romano M
    Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine.
    N Engl J Med. 2022;387.
    PubMed    


  69. COHEN-STAVI CJ, Magen O, Barda N, Yaron S, et al
    BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age.
    N Engl J Med. 2022 Jun 29. doi: 10.1056/NEJMoa2205011.
    PubMed     Abstract available


  70. BOUCAU J, Marino C, Regan J, Uddin R, et al
    Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection.
    N Engl J Med. 2022 Jun 29. doi: 10.1056/NEJMc2202092.
    PubMed    


  71. LAUNAY O, Cachanado M, Luong Nguyen LB, Ninove L, et al
    Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine.
    N Engl J Med. 2022 Jun 29. doi: 10.1056/NEJMc2206711.
    PubMed    


  72. SCHONBORN L, Seck SE, Thiele T, Warkentin TE, et al
    SARS-CoV-2 Infection in Patients with a History of VITT.
    N Engl J Med. 2022 Jun 27. doi: 10.1056/NEJMc2206601.
    PubMed    


  73. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Vaccinating Young Children against Covid-19.
    N Engl J Med. 2022;386:e77.
    PubMed    


  74. GRIFFIN MR
    A Challenge to Respiratory Syncytial Virus Illness in Adults.
    N Engl J Med. 2022;386:2427-2428.
    PubMed    


  75. SCHMOELE-THOMA B, Zareba AM, Jiang Q, Maddur MS, et al
    Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.
    N Engl J Med. 2022;386:2377-2386.
    PubMed     Abstract available


  76. HACHMANN NP, Miller J, Collier AY, Ventura JD, et al
    Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5.
    N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMc2206576.
    PubMed    


  77. DESILVA M, Haapala J, Vazquez-Benitez G, Vesco KK, et al
    Evaluation of Acute Adverse Events after Covid-19 Vaccination during Pregnancy.
    N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMc2205276.
    PubMed    


  78. HALASA NB, Olson SM, Staat MA, Newhams MM, et al
    Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants.
    N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMoa2204399.
    PubMed     Abstract available


  79. RASMUSSEN SA, Jamieson DJ
    Covid-19 Vaccination during Pregnancy - Two for the Price of One.
    N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMe2206730.
    PubMed    


  80. RUBIN EJ, Baden LR, Abraham J, Morrissey S, et al
    Audio Interview: Viral Evolution and the Future of Monoclonal Antibodies.
    N Engl J Med. 2022;386:e75.
    PubMed    


  81. LEUCHTER RK, Jackson NJ, Mafi JN, Sarkisian CA, et al
    Association between Covid-19 Vaccination and Influenza Vaccination Rates.
    N Engl J Med. 2022 Jun 15. doi: 10.1056/NEJMc2204560.
    PubMed    


  82. QU P, Faraone J, Evans JP, Zou X, et al
    Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants.
    N Engl J Med. 2022 Jun 15. doi: 10.1056/NEJMc2206725.
    PubMed    


  83. HOPKINS S, Hall V, Klenerman P
    Protection against SARS-CoV-2 after Vaccination and Previous Infection. Reply.
    N Engl J Med. 2022;386.
    PubMed    


  84. MATUCHANSKY C
    Protection against SARS-CoV-2 after Vaccination and Previous Infection.
    N Engl J Med. 2022;386.
    PubMed    


  85. ALTARAWNEH HN, Chemaitelly H, Ayoub HH, Tang P, et al
    Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.
    N Engl J Med. 2022 Jun 15. doi: 10.1056/NEJMoa2203965.
    PubMed     Abstract available


  86. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Protecting the Immunocompromised from Covid-19.
    N Engl J Med. 2022;386:e71.
    PubMed    


  87. ABRAHAM J
    Monoclonal Antibodies with Extended Half-Life to Prevent Covid-19.
    N Engl J Med. 2022;386:2236-2238.
    PubMed    


  88. JOLOBE OMP
    Protection Due to Previous SARS-CoV-2 Infection.
    N Engl J Med. 2022;386.
    PubMed    


  89. SCHERER EM, Babiker A, Adelman MW, Allman B, et al
    SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients.
    N Engl J Med. 2022 Jun 8. doi: 10.1056/NEJMc2202861.
    PubMed    


  90. RUBIN EJ, Baden LR, Moore PL, Morrissey S, et al
    Audio Interview: Dissecting the Host Response to SARS-CoV-2.
    N Engl J Med. 2022;386:e69.
    PubMed    


    May 2022
  91. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Waning Immunity against Covid-19.
    N Engl J Med. 2022;386:e64.
    PubMed    


  92. GOLDBERG Y, Mandel M, Bar-On YM, Bodenheimer O, et al
    Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2.
    N Engl J Med. 2022 May 25. doi: 10.1056/NEJMoa2118946.
    PubMed     Abstract available


  93. ACCORSI EK, Britton A, Shang N, Fleming-Dutra KE, et al
    Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron.
    N Engl J Med. 2022 May 25. doi: 10.1056/NEJMc2203165.
    PubMed    


  94. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: What to Make of Covid-19 Hot Spots.
    N Engl J Med. 2022;386:e63.
    PubMed    


  95. BROWN PE, Fu SH, Bansal A, Newcombe L, et al
    Omicron BA.1/1.1 SARS-CoV-2 Infection among Vaccinated Canadian Adults.
    N Engl J Med. 2022 May 18. doi: 10.1056/NEJMc2202879.
    PubMed    


  96. EVANS JP, Qu P, Zeng C, Zheng YM, et al
    Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants.
    N Engl J Med. 2022 May 18. doi: 10.1056/NEJMc2205019.
    PubMed    


  97. RUBIN EJ, Baden LR, Lipsitch M, Morrissey S, et al
    Audio Interview: Forecasting the Future of Covid.
    N Engl J Med. 2022;386:e58.
    PubMed    


  98. CREECH CB, Anderson E, Berthaud V, Yildirim I, et al
    Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age.
    N Engl J Med. 2022 May 11. doi: 10.1056/NEJMoa2203315.
    PubMed     Abstract available


  99. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Do We Need New Covid-19 Vaccines?
    N Engl J Med. 2022;386:e52.
    PubMed    


  100. ESTCOURT L, Callum J
    Convalescent Plasma for Covid-19 - Making Sense of the Inconsistencies.
    N Engl J Med. 2022;386:1753-1754.
    PubMed    


  101. HAGER KJ, Perez Marc G, Gobeil P, Diaz RS, et al
    Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine.
    N Engl J Med. 2022 May 4. doi: 10.1056/NEJMoa2201300.
    PubMed     Abstract available


  102. DAI L, Gao L, Tao L, Hadinegoro SR, et al
    Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults.
    N Engl J Med. 2022 May 4. doi: 10.1056/NEJMoa2202261.
    PubMed     Abstract available


  103. NOHYNEK H, Wilder-Smith A
    Does the World Still Need New Covid-19 Vaccines?
    N Engl J Med. 2022 May 4. doi: 10.1056/NEJMe2204695.
    PubMed    


  104. GRAY G, Collie S, Goga A, Garrett N, et al
    Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa.
    N Engl J Med. 2022 May 4. doi: 10.1056/NEJMc2202061.
    PubMed    


  105. PERSAD G, Pandya A
    A Comprehensive Covid-19 Response - The Need for Economic Evaluation.
    N Engl J Med. 2022 May 4. doi: 10.1056/NEJMp2202828.
    PubMed    


    April 2022
  106. RUBIN EJ, Baden LR, Marrazzo JM, Morrissey S, et al
    Audio Interview: Communicating Covid-19 Science.
    N Engl J Med. 2022;386:e53.
    PubMed    


  107. SIMOES EAF, Center KJ, Tita ATN, Swanson KA, et al
    Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy.
    N Engl J Med. 2022;386:1615-1626.
    PubMed     Abstract available


  108. RUBIN EJ, Baden LR, Inglefinger JR, Morrissey S, et al
    Audio Interview: The Effects of Covid-19 on Children.
    N Engl J Med. 2022;386:e51.
    PubMed    


  109. BHATTACHARYYA RP, Hanage WP
    Intrinsic Severity of the SARS-CoV-2 Omicron Variant. Reply.
    N Engl J Med. 2022 Apr 20. pii: 10.1056/NEJMc2203679.
    PubMed    


  110. SHAFER SL
    Intrinsic Severity of the SARS-CoV-2 Omicron Variant.
    N Engl J Med. 2022 Apr 20. pii: 10.1056/NEJMc2203679.
    PubMed    


  111. LEVIN MJ, Ustianowski A, De Wit S, Launay O, et al
    Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
    N Engl J Med. 2022 Apr 20. doi: 10.1056/NEJMoa2116620.
    PubMed     Abstract available


  112. OFFIT PA
    Covid-19 Boosters - Where from Here?
    N Engl J Med. 2022 Apr 13. doi: 10.1056/NEJMe2203329.
    PubMed    


  113. MAGEN O, Waxman JG, Makov-Assif M, Vered R, et al
    Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
    N Engl J Med. 2022 Apr 13. doi: 10.1056/NEJMoa2201688.
    PubMed     Abstract available


  114. DRAIN PK
    Rapid Diagnostic Testing for SARS-CoV-2. Reply.
    N Engl J Med. 2022;386.
    PubMed    


  115. BOGATY P
    Rapid Diagnostic Testing for SARS-CoV-2.
    N Engl J Med. 2022;386.
    PubMed    


  116. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Do We Need a Fourth Dose of Covid Vaccine?
    N Engl J Med. 2022;386:e45.
    PubMed    


  117. MOORE PL, Baden LR
    Omicron - Decoupling Infection from Severe Disease.
    N Engl J Med. 2022;386:1361-1362.
    PubMed    


  118. HORWITZ JR, Wiley LF
    Not Ready for the End Game - Why Ending Federal Covid-19 Emergency Declarations Will Harm Access to Care.
    N Engl J Med. 2022 Apr 6. doi: 10.1056/NEJMp2203468.
    PubMed    


  119. YOON SK, Hegmann KT, Thiese MS, Burgess JL, et al
    Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers.
    N Engl J Med. 2022 Apr 6. doi: 10.1056/NEJMc2201821.
    PubMed    


  120. LEE KC, Morgan AU, Chaiyachati KH, Asch DA, et al
    Pulse Oximetry for Monitoring Patients with Covid-19 at Home - A Pragmatic, Randomized Trial.
    N Engl J Med. 2022 Apr 6. doi: 10.1056/NEJMc2201541.
    PubMed    


  121. BAR-ON YM, Goldberg Y, Mandel M, Bodenheimer O, et al
    Protection by a Fourth Dose of BNT162b2 against Omicron in Israel.
    N Engl J Med. 2022 Apr 5. doi: 10.1056/NEJMoa2201570.
    PubMed     Abstract available


    March 2022
  122. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Effectiveness of Covid-19 Vaccination in Children.
    N Engl J Med. 2022;386:e39.
    PubMed    


  123. KLEIN NP
    Added Benefit of Covid-19 Vaccination after Previous Infection.
    N Engl J Med. 2022;386:1278-1279.
    PubMed    


  124. REIS G, Silva EASM, Silva DCM, Thabane L, et al
    Effect of Early Treatment with Ivermectin among Patients with Covid-19.
    N Engl J Med. 2022 Mar 30. doi: 10.1056/NEJMoa2115869.
    PubMed     Abstract available


  125. SULLIVAN DJ, Gebo KA, Shoham S, Bloch EM, et al
    Early Outpatient Treatment for Covid-19 with Convalescent Plasma.
    N Engl J Med. 2022 Mar 30. doi: 10.1056/NEJMoa2119657.
    PubMed     Abstract available


  126. PRICE AM, Olson SM, Newhams MM, Halasa NB, et al
    BNT162b2 Protection against the Omicron Variant in Children and Adolescents.
    N Engl J Med. 2022 Mar 30. doi: 10.1056/NEJMoa2202826.
    PubMed     Abstract available


  127. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Covid-19: Why We Publish What We Do.
    N Engl J Med. 2022;386:e38.
    PubMed    


  128. VYAS JM, Castle AC, Bourgouin PP, Turbett SE, et al
    Case 9-2022: A 56-Year-Old Woman with Fever, Myalgias, Diarrhea, and Cough.
    N Engl J Med. 2022;386:1166-1174.
    PubMed    


  129. ROSSLER A, Knabl L, von Laer D, Kimpel J, et al
    Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection.
    N Engl J Med. 2022 Mar 23. doi: 10.1056/NEJMc2201607.
    PubMed    


  130. MOREIRA ED JR, Kitchin N, Xu X, Dychter SS, et al
    Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
    N Engl J Med. 2022 Mar 23. doi: 10.1056/NEJMoa2200674.
    PubMed     Abstract available


  131. QI X, Qiu H, Hao S, Zhu F, et al
    Human Infection with an Avian-Origin Influenza A (H10N3) Virus.
    N Engl J Med. 2022;386:1087-1088.
    PubMed    


  132. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Can We Make More Effective Covid-19 Vaccines?
    N Engl J Med. 2022;386:e36.
    PubMed    


  133. DE ANDA C, Johnson MG, Pedley A
    Molnupiravir for Covid-19 in Nonhospitalized Patients. Reply.
    N Engl J Med. 2022;386.
    PubMed    


  134. ROBERFROID D, Jespers V, Hulstaert F
    Molnupiravir for Covid-19 in Nonhospitalized Patients.
    N Engl J Med. 2022;386.
    PubMed    


  135. LEVENSTEIN S
    Molnupiravir for Covid-19 in Nonhospitalized Patients.
    N Engl J Med. 2022;386.
    PubMed    


  136. SELVI-SABATER P, Abellon-Ruiz J
    Molnupiravir for Covid-19 in Nonhospitalized Patients.
    N Engl J Med. 2022;386.
    PubMed    


  137. THORLUND K, Sheldrick K, Mills E
    Molnupiravir for Covid-19 in Nonhospitalized Patients.
    N Engl J Med. 2022;386.
    PubMed    


  138. REGEV-YOCHAY G, Gonen T, Gilboa M, Mandelboim M, et al
    Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron.
    N Engl J Med. 2022 Mar 16. doi: 10.1056/NEJMc2202542.
    PubMed    


  139. SHAPIRO AE, Gupta A
    Early Treatment with Sotrovimab for Covid-19. Reply.
    N Engl J Med. 2022 Mar 16. pii: 10.1056/NEJMc2201606.
    PubMed    


  140. FUJIWARA Y
    Early Treatment with Sotrovimab for Covid-19.
    N Engl J Med. 2022 Mar 16. pii: 10.1056/NEJMc2201606.
    PubMed    


  141. ORIGUEN J, Caro-Teller JM, Lopez-Medrano F
    Early Treatment with Sotrovimab for Covid-19.
    N Engl J Med. 2022 Mar 16. pii: 10.1056/NEJMc2201606.
    PubMed    


  142. HATZL S, Krause R, Schilcher G
    Early Treatment with Sotrovimab for Covid-19.
    N Engl J Med. 2022 Mar 16. pii: 10.1056/NEJMc2201606.
    PubMed    


  143. YU J, Collier AY, Rowe M, Mardas F, et al
    Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants.
    N Engl J Med. 2022 Mar 16. doi: 10.1056/NEJMc2201849.
    PubMed    


  144. RUBIN EJ, Baden LR, Hunter D, Morrissey S, et al
    Audio Interview: Making Covid-19 Vaccines Available around the World.
    N Engl J Med. 2022;386:e31.
    PubMed    


  145. TAKASHITA E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, et al
    Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.
    N Engl J Med. 2022 Mar 9. doi: 10.1056/NEJMc2201933.
    PubMed    


  146. ROCKETT R, Basile K, Maddocks S, Fong W, et al
    Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use.
    N Engl J Med. 2022 Mar 9. doi: 10.1056/NEJMc2120219.
    PubMed    


  147. ABU-RADDAD LJ, Chemaitelly H, Ayoub HH, AlMukdad S, et al
    Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
    N Engl J Med. 2022 Mar 9. doi: 10.1056/NEJMoa2200797.
    PubMed     Abstract available


  148. MONTO AS
    The Future of SARS-CoV-2 Vaccination. Reply.
    N Engl J Med. 2022;386:899-900.
    PubMed    


  149. BACHMANN MF, Mohsen MO, Speiser DE
    The Future of SARS-CoV-2 Vaccination.
    N Engl J Med. 2022;386:899.
    PubMed    


  150. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Using Our Covid-19 Experience to Develop Vaccines More Quickly.
    N Engl J Med. 2022;386:e29.
    PubMed    


  151. DOMACHOWSKE J, Madhi SA, Simoes EAF, Atanasova V, et al
    Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.
    N Engl J Med. 2022;386:892-894.
    PubMed    


  152. GEE JE, Bower WA, Kunkel A, Petras J, et al
    Multistate Outbreak of Melioidosis Associated with Imported Aromatherapy Spray.
    N Engl J Med. 2022;386:861-868.
    PubMed     Abstract available


  153. HAMMITT LL, Dagan R, Yuan Y, Baca Cots M, et al
    Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
    N Engl J Med. 2022;386:837-846.
    PubMed     Abstract available


  154. MELLO MM, Parmet WE
    U.S. Public Health Law - Foundations and Emerging Shifts.
    N Engl J Med. 2022;386:805-808.
    PubMed    


  155. WALTER EB, Talaat KR, Gurtman A
    More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. Reply.
    N Engl J Med. 2022;386.
    PubMed    


  156. LEIBOWITZ R, Schurr E, Hirsch O
    More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
    N Engl J Med. 2022;386.
    PubMed    


  157. TAYTARD J, Prevost B, Corvol H
    More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
    N Engl J Med. 2022;386.
    PubMed    


  158. ANDREWS N, Stowe J, Kirsebom F, Toffa S, et al
    Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.
    N Engl J Med. 2022 Mar 2. doi: 10.1056/NEJMoa2119451.
    PubMed     Abstract available


  159. SAVILLE M, Cramer JP, Downham M, Hacker A, et al
    Delivering Pandemic Vaccines in 100 Days - What Will It Take?
    N Engl J Med. 2022 Mar 2. doi: 10.1056/NEJMp2202669.
    PubMed    


    February 2022
  160. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Understanding the Omicron Variant of SARS-CoV-2.
    N Engl J Med. 2022;386:e27.
    PubMed    


  161. HUNTER DJ, Abdool Karim SS, Baden LR, Farrar JJ, et al
    Addressing Vaccine Inequity - Covid-19 Vaccines as a Global Public Good.
    N Engl J Med. 2022 Feb 23. doi: 10.1056/NEJMe2202547.
    PubMed    


  162. MADHI SA, Kwatra G, Myers JE, Jassat W, et al
    Population Immunity and Covid-19 Severity with Omicron Variant in South Africa.
    N Engl J Med. 2022 Feb 23. doi: 10.1056/NEJMoa2119658.
    PubMed     Abstract available


  163. ANDERSON LJ, Walsh EE
    The Challenge of Respiratory Syncytial Virus Human Challenge Studies.
    N Engl J Med. 2022;386:696-697.
    PubMed    


  164. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: A New Antiviral against Covid-19.
    N Engl J Med. 2022;386:e25.
    PubMed    


  165. AHMAD A, Eze K, Noulin N, Horvathova V, et al
    EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.
    N Engl J Med. 2022;386:655-666.
    PubMed     Abstract available


  166. FLEISHER LA, Schreiber M, Cardo D, Srinivasan A, et al
    Health Care Safety during the Pandemic and Beyond - Building a System That Ensures Resilience.
    N Engl J Med. 2022;386:609-611.
    PubMed    


  167. GOTTLIEB RL, Juneja K, Hill JA
    Outpatient Remdesivir to Prevent Progression to Severe Covid-19. Reply.
    N Engl J Med. 2022 Feb 16. pii: 10.1056/NEJMc2200591.
    PubMed    


  168. ENNEZAT PV
    Outpatient Remdesivir to Prevent Progression to Severe Covid-19.
    N Engl J Med. 2022 Feb 16. pii: 10.1056/NEJMc2200591.
    PubMed    


  169. HAMMERMAN A, Sergienko R, Friger M, Beckenstein T, et al
    Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19.
    N Engl J Med. 2022 Feb 16. doi: 10.1056/NEJMoa2119497.
    PubMed     Abstract available


  170. HALL V, Foulkes S, Insalata F, Kirwan P, et al
    Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection.
    N Engl J Med. 2022 Feb 16. doi: 10.1056/NEJMoa2118691.
    PubMed     Abstract available


  171. HAMMOND J, Leister-Tebbe H, Gardner A, Abreu P, et al
    Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
    N Engl J Med. 2022 Feb 16. doi: 10.1056/NEJMoa2118542.
    PubMed     Abstract available


  172. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Covid-19 as an Endemic Disease.
    N Engl J Med. 2022;386:e21.
    PubMed    


  173. ARBEL R, Sergienko R, Hammerman A
    BNT162b2 Vaccine Booster and Covid-19 Mortality. Reply.
    N Engl J Med. 2022 Feb 9. pii: 10.1056/NEJMc2120044.
    PubMed    


  174. SADOFF J, Gray G, Vandebosch A, Cardenas V, et al
    Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.
    N Engl J Med. 2022 Feb 9. doi: 10.1056/NEJMoa2117608.
    PubMed     Abstract available


  175. PILZ S
    BNT162b2 Vaccine Booster and Covid-19 Mortality.
    N Engl J Med. 2022 Feb 9. pii: 10.1056/NEJMc2120044.
    PubMed    


  176. ROHBAN T
    BNT162b2 Vaccine Booster and Covid-19 Mortality.
    N Engl J Med. 2022 Feb 9. pii: 10.1056/NEJMc2120044.
    PubMed    


  177. ALTARAWNEH HN, Chemaitelly H, Hasan MR, Ayoub HH, et al
    Protection against the Omicron Variant from Previous SARS-CoV-2 Infection.
    N Engl J Med. 2022 Feb 9. doi: 10.1056/NEJMc2200133.
    PubMed    


  178. MAYR FB, Talisa VB, Shaikh O, Yende S, et al
    Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans.
    N Engl J Med. 2022 Feb 9. doi: 10.1056/NEJMc2200415.
    PubMed    


  179. RUBIN EJ, Baden LR, Rosen CJ, Morrissey S, et al
    Audio Interview: Studying Long Covid.
    N Engl J Med. 2022;386:e20.
    PubMed    


  180. BRAGA NETO MB, Badley AD, Parikh SA, Graham RP, et al
    Calm before the Storm.
    N Engl J Med. 2022;386:479-485.
    PubMed    


  181. MURPHY WJ, Longo DL
    Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination. Reply.
    N Engl J Med. 2022 Feb 2. pii: 10.1056/NEJMc2119443.
    PubMed    


  182. HARVILLE TO, Arthur JM
    Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination.
    N Engl J Med. 2022 Feb 2. pii: 10.1056/NEJMc2119443.
    PubMed    


  183. DE MARIA A
    Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination.
    N Engl J Med. 2022 Feb 2. pii: 10.1056/NEJMc2119443.
    PubMed    


  184. BHATTACHARYYA RP, Hanage WP
    Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant.
    N Engl J Med. 2022 Feb 2. doi: 10.1056/NEJMp2119682.
    PubMed    


    January 2022
  185. RUBIN EJ, Baden LR, Barocas JA, Morrissey S, et al
    Audio Interview: Addressing the Omicron Variant of SARS-CoV-2.
    N Engl J Med. 2022;386:e16.
    PubMed    


  186. TAKASHITA E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, et al
    Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant.
    N Engl J Med. 2022 Jan 26. doi: 10.1056/NEJMc2119407.
    PubMed    


  187. ABU-RADDAD LJ, Chemaitelly H, Bertollini R
    Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar.
    N Engl J Med. 2022 Jan 26. doi: 10.1056/NEJMc2119432.
    PubMed    


  188. ROACH A, Chikwe J, Catarino P, Rampolla R, et al
    Lung Transplantation for Covid-19-Related Respiratory Failure in the United States.
    N Engl J Med. 2022 Jan 26. doi: 10.1056/NEJMc2117024.
    PubMed    


  189. RUBIN EJ, Baden LR, Fineberg HV, Morrissey S, et al
    Audio Interview: Crushing the Covid-19 Curve.
    N Engl J Med. 2022;386:e13.
    PubMed    


  190. WALTER EB, Talaat KR, Gurtman A
    BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. Reply.
    N Engl J Med. 2022;386.
    PubMed    


  191. MINTZKER Y
    BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
    N Engl J Med. 2022;386.
    PubMed    


  192. FANG SF, Liu N, Du HW
    BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
    N Engl J Med. 2022;386.
    PubMed    


  193. ABU-RADDAD LJ, Chemaitelly H, Bertollini R
    Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar.
    N Engl J Med. 2022 Jan 19. doi: 10.1056/NEJMc2117933.
    PubMed    


  194. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Covid-19 Takeaways at Podcast 100.
    N Engl J Med. 2022;386:e11.
    PubMed    


  195. WEINSTEIN DF
    Reengineering GME in a Pandemic - Looking Back, and Forward.
    N Engl J Med. 2022;386:97.
    PubMed    


  196. ANDREWS N, Tessier E, Stowe J, Gower C, et al
    Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines.
    N Engl J Med. 2022 Jan 12. doi: 10.1056/NEJMoa2115481.
    PubMed     Abstract available


  197. EDWARDS KM
    Sparing of Severe Covid-19 in Vaccinated Adolescents.
    N Engl J Med. 2022 Jan 12. doi: 10.1056/NEJMe2118471.
    PubMed    


  198. ROSSLER A, Riepler L, Bante D, von Laer D, et al
    SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons.
    N Engl J Med. 2022 Jan 12. doi: 10.1056/NEJMc2119236.
    PubMed    


  199. OLSON SM, Newhams MM, Halasa NB, Price AM, et al
    Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents.
    N Engl J Med. 2022 Jan 12. doi: 10.1056/NEJMoa2117995.
    PubMed     Abstract available


  200. LIN DY, Gu Y, Wheeler B, Young H, et al
    Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina.
    N Engl J Med. 2022 Jan 12. doi: 10.1056/NEJMoa2117128.
    PubMed     Abstract available


  201. DRAIN PK
    Rapid Diagnostic Testing for SARS-CoV-2.
    N Engl J Med. 2022 Jan 7. doi: 10.1056/NEJMcp2117115.
    PubMed    


  202. RUBIN EJ, Baden LR, Drosten C, Morrissey S, et al
    Audio Interview: Covid-19 - The Outlook in Europe.
    N Engl J Med. 2022;386:e9.
    PubMed    


  203. GONEN T, Lustig Y, Regev-Yochay G
    Covid-19 Infections in Vaccinated Health Care Workers. Reply.
    N Engl J Med. 2022;386.
    PubMed    


  204. RASTMANESH R
    Covid-19 Infections in Vaccinated Health Care Workers.
    N Engl J Med. 2022;386.
    PubMed    


  205. EYRE DW, Taylor D, Purver M, Chapman D, et al
    Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants.
    N Engl J Med. 2022 Jan 5. doi: 10.1056/NEJMoa2116597.
    PubMed     Abstract available


  206. PAI M, Kasaeva T, Swaminathan S
    Covid-19's Devastating Effect on Tuberculosis Care - A Path to Recovery.
    N Engl J Med. 2022 Jan 5. doi: 10.1056/NEJMp2118145.
    PubMed    


    December 2021
  207. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Covid-19 Vaccination and the Omicron Variant.
    N Engl J Med. 2021;385:e102.
    PubMed    


  208. RITTENBERG E
    Trust, Faith, and Covid.
    N Engl J Med. 2021;385:2504-2505.
    PubMed    


  209. SCHMIDT F, Muecksch F, Weisblum Y, Da Silva J, et al
    Plasma Neutralization of the SARS-CoV-2 Omicron Variant.
    N Engl J Med. 2021 Dec 30. doi: 10.1056/NEJMc2119641.
    PubMed    


  210. MCGREW S, Taylor HA
    Adolescents, Parents, and Covid-19 Vaccination - Who Should Decide?
    N Engl J Med. 2021 Dec 29. doi: 10.1056/NEJMp2116771.
    PubMed    


  211. NEMET I, Kliker L, Lustig Y, Zuckerman N, et al
    Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.
    N Engl J Med. 2021 Dec 29. doi: 10.1056/NEJMc2119358.
    PubMed    


  212. KISSLER SM, Fauver JR, Mack C, Tai CG, et al
    Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons.
    N Engl J Med. 2021;385:2489-2491.
    PubMed    


  213. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: A Potential New Agent to Treat Covid-19.
    N Engl J Med. 2021;385:e101.
    PubMed    


  214. GENG LN, Verghese A, Tilburt JC
    Consultative Medicine - An Emerging Specialty for Patients with Perplexing Conditions.
    N Engl J Med. 2021;385:2478-2484.
    PubMed    


  215. FOXWORTH R, Redvers N, Moreno MA, Lopez-Carmen VA, et al
    Covid-19 Vaccination in American Indians and Alaska Natives - Lessons from Effective Community Responses.
    N Engl J Med. 2021;385:2403-2406.
    PubMed    


  216. GOTTLIEB RL, Vaca CE, Paredes R, Mera J, et al
    Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
    N Engl J Med. 2021 Dec 22. doi: 10.1056/NEJMoa2116846.
    PubMed     Abstract available


  217. MUHSEN K, Maimon N, Mizrahi A, Varticovschi B, et al
    Effects of BNT162b2 Covid-19 Vaccine Booster in Long-Term Care Facilities in Israel.
    N Engl J Med. 2021 Dec 22. doi: 10.1056/NEJMc2117385.
    PubMed    


  218. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: How Much Protection Does Prior SARS-CoV-2 Infection Provide?
    N Engl J Med. 2021;385:e100.
    PubMed    


  219. WHITLEY R
    Molnupiravir - A Step toward Orally Bioavailable Therapies for Covid-19.
    N Engl J Med. 2021 Dec 16. doi: 10.1056/NEJMe2117814.
    PubMed    


  220. JAYK BERNAL A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, et al
    Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
    N Engl J Med. 2021 Dec 16. doi: 10.1056/NEJMoa2116044.
    PubMed     Abstract available


  221. CHEMAITELLY H, Bertollini R, Abu-Raddad LJ
    Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant.
    N Engl J Med. 2021 Dec 15. doi: 10.1056/NEJMc2110300.
    PubMed    


  222. HORTON LE, Abeles SR, Torriani FJ
    SARS-CoV-2 Infection in Vaccinated Health Care Workers. Reply.
    N Engl J Med. 2021 Dec 15. pii: 10.1056/NEJMc2117119.
    PubMed    


  223. LILLERI D, Marena C, Baldanti F
    SARS-CoV-2 Infection in Vaccinated Health Care Workers.
    N Engl J Med. 2021 Dec 15. pii: 10.1056/NEJMc2117119.
    PubMed    


  224. MORENS DM, Taubenberger JK, Fauci AS
    Universal Coronavirus Vaccines - An Urgent Need.
    N Engl J Med. 2021 Dec 15. doi: 10.1056/NEJMp2118468.
    PubMed    


  225. DUNKLE LM, Kotloff KL, Gay CL, Anez G, et al
    Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
    N Engl J Med. 2021 Dec 15. doi: 10.1056/NEJMoa2116185.
    PubMed     Abstract available


  226. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Waning Immunity against SARS-CoV-2.
    N Engl J Med. 2021;385:e99.
    PubMed    


  227. KNUDSEN J, Chokshi DA
    Covid-19 and the Safety Net - Moving from Straining to Sustaining.
    N Engl J Med. 2021;385:2209-2211.
    PubMed    


  228. ARBEL R, Hammerman A, Sergienko R, Friger M, et al
    BNT162b2 Vaccine Booster and Mortality Due to Covid-19.
    N Engl J Med. 2021 Dec 8. doi: 10.1056/NEJMoa2115624.
    PubMed     Abstract available


  229. BAR-ON YM, Goldberg Y, Mandel M, Bodenheimer O, et al
    Protection against Covid-19 by BNT162b2 Booster across Age Groups.
    N Engl J Med. 2021 Dec 8. doi: 10.1056/NEJMoa2115926.
    PubMed     Abstract available


  230. WALKER AS, Vihta KD, Gethings O, Pritchard E, et al
    Tracking the Emergence of SARS-CoV-2 Alpha Variant in the United Kingdom.
    N Engl J Med. 2021 Dec 8. doi: 10.1056/NEJMc2103227.
    PubMed    


  231. MCGARRY BE, Barnett ML, Grabowski DC, Gandhi AD, et al
    Nursing Home Staff Vaccination and Covid-19 Outcomes.
    N Engl J Med. 2021 Dec 8. doi: 10.1056/NEJMc2115674.
    PubMed    


  232. RUBIN EJ, Baden LR, Abdool Karim SS, Morrissey S, et al
    Audio Interview: The Omicron Variant of SARS-CoV-2.
    N Engl J Med. 2021;385:e96.
    PubMed    


  233. CAFORIO ALP
    Receipt of mRNA Vaccine against Covid-19 and Myocarditis.
    N Engl J Med. 2021;385:2189-2190.
    PubMed    


  234. RUBIN EJ, Longo DL
    Covid-19 mRNA Vaccines - Six of One, Half a Dozen of the Other.
    N Engl J Med. 2021 Dec 1. doi: 10.1056/NEJMe2117446.
    PubMed    


  235. ROSENBERG ES, Dorabawila V, Easton D, Bauer UE, et al
    Covid-19 Vaccine Effectiveness in New York State.
    N Engl J Med. 2021 Dec 1. doi: 10.1056/NEJMoa2116063.
    PubMed     Abstract available


  236. DICKERMAN BA, Gerlovin H, Madenci AL, Kurgansky KE, et al
    Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans.
    N Engl J Med. 2021 Dec 1. doi: 10.1056/NEJMoa2115463.
    PubMed     Abstract available


    November 2021
  237. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: What's Gone Right in Our Battle against Covid-19.
    N Engl J Med. 2021;385:e95.
    PubMed    


  238. ABU-RADDAD LJ, Chemaitelly H, Bertollini R
    Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections.
    N Engl J Med. 2021 Nov 24. doi: 10.1056/NEJMc2108120.
    PubMed    


  239. MURPHY WJ, Longo DL
    A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination.
    N Engl J Med. 2021 Nov 24. doi: 10.1056/NEJMcibr2113694.
    PubMed    


  240. ZARYCHANSKI R, Lawler PR, Goligher E
    Therapeutic Anticoagulation with Heparin in Patients with Covid-19. Reply.
    N Engl J Med. 2021;385:2014.
    PubMed    


  241. FERNANDES TM, McGuire WC, Morris TA
    Therapeutic Anticoagulation with Heparin in Patients with Covid-19.
    N Engl J Med. 2021;385:2013.
    PubMed    


  242. STERPETTI AV
    Therapeutic Anticoagulation with Heparin in Patients with Covid-19.
    N Engl J Med. 2021;385:2013-2014.
    PubMed    


  243. RUBIN EJ, Baden LR, Mello MM, Morrissey S, et al
    Audio Interview: The Legal Basis for Covid-19 Restrictions and Mandates.
    N Engl J Med. 2021;385:e88.
    PubMed    


  244. RUBIN EJ, Baden LR, Grinsztejn B, Morrissey S, et al
    Audio Interview: Covid-19 in Brazil and New Evidence for Vaccinating Younger Children.
    N Engl J Med. 2021;385:e79.
    PubMed    


  245. LOPEZ BERNAL J, Gower C, Andrews N
    Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. Reply.
    N Engl J Med. 2021 Nov 10. pii: 10.1056/NEJMc2113090.
    PubMed    


  246. EMANI VR, Reddy R, Goswami S
    Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
    N Engl J Med. 2021 Nov 10. pii: 10.1056/NEJMc2113090.
    PubMed    


  247. LINSENMEYER K, Gupta K, Charness ME
    Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
    N Engl J Med. 2021 Nov 10. pii: 10.1056/NEJMc2113090.
    PubMed    


  248. TORGOVNICK J
    Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
    N Engl J Med. 2021 Nov 10. pii: 10.1056/NEJMc2113090.
    PubMed    


  249. MONTO AS
    The Future of SARS-CoV-2 Vaccination - Lessons from Influenza.
    N Engl J Med. 2021 Nov 6. doi: 10.1056/NEJMp2113403.
    PubMed    


  250. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Do We Have the Tools to End the Covid-19 Pandemic?
    N Engl J Med. 2021;385:e78.
    PubMed    


  251. SCULLY M
    VITT after ChAdOx1 nCoV-19 Vaccination. Reply.
    N Engl J Med. 2021 Nov 3. pii: 10.1056/NEJMc2111026.
    PubMed    


  252. GREINACHER A, Schonborn L, Thiele T
    VITT after ChAdOx1 nCoV-19 Vaccination. Reply.
    N Engl J Med. 2021 Nov 3. pii: 10.1056/NEJMc2111026.
    PubMed    


  253. WEBER C, von Hundelshausen P, Siess W
    VITT after ChAdOx1 nCoV-19 Vaccination.
    N Engl J Med. 2021 Nov 3. pii: 10.1056/NEJMc2111026.
    PubMed    


  254. SANTIN AD
    VITT after ChAdOx1 nCoV-19 Vaccination.
    N Engl J Med. 2021 Nov 3. pii: 10.1056/NEJMc2111026.
    PubMed    


  255. URIU K, Kimura I, Shirakawa K, Takaori-Kondo A, et al
    Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum.
    N Engl J Med. 2021 Nov 3. doi: 10.1056/NEJMc2114706.
    PubMed    


    October 2021
  256. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: A New Monoclonal Antibody for Covid-19 and Potential Vaccination for Children.
    N Engl J Med. 2021;385:e74.
    PubMed    


  257. CHIN MH
    Uncomfortable Truths - What Covid-19 Has Revealed about Chronic-Disease Care in America.
    N Engl J Med. 2021;385:1633-1636.
    PubMed    


  258. ASKENASE PW
    Rare Skin Reactions after mRNA Vaccination, Similar to Jones-Mote Basophil Responses.
    N Engl J Med. 2021;385:1720-1721.
    PubMed    


  259. GUPTA A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, et al
    Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.
    N Engl J Med. 2021 Oct 27. doi: 10.1056/NEJMoa2107934.
    PubMed     Abstract available


  260. GOLDBERG Y, Mandel M, Bar-On YM, Bodenheimer O, et al
    Waning Immunity after the BNT162b2 Vaccine in Israel.
    N Engl J Med. 2021 Oct 27. doi: 10.1056/NEJMoa2114228.
    PubMed     Abstract available


  261. DAGAN N, Barda N, Balicer RD
    Adverse Effects after BNT162b2 Vaccine and SARS-CoV-2 Infection, According to Age and Sex.
    N Engl J Med. 2021 Oct 27. doi: 10.1056/NEJMc2115045.
    PubMed    


  262. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: A New Look at Covid-19 Vaccine Boosters.
    N Engl J Med. 2021;385:e72.
    PubMed    


  263. MALLETT SD
    Peak Moments - When Kindergarten Is High Risk.
    N Engl J Med. 2021;385:1543-1545.
    PubMed    


  264. MAGNUS MC, Gjessing HK, Eide HN, Wilcox AJ, et al
    Covid-19 Vaccination during Pregnancy and First-Trimester Miscarriage.
    N Engl J Med. 2021 Oct 20. doi: 10.1056/NEJMc2114466.
    PubMed    


  265. TEMPLE C, Hoang R, Hendrickson RG
    Toxic Effects from Ivermectin Use Associated with Prevention and Treatment of Covid-19.
    N Engl J Med. 2021 Oct 20. doi: 10.1056/NEJMc2114907.
    PubMed    


  266. CHIN ET, Leidner D, Zhang Y, Long E, et al
    Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison.
    N Engl J Med. 2021 Oct 20. doi: 10.1056/NEJMc2114089.
    PubMed    


  267. SHEIKH A, Robertson C, Taylor B
    BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant.
    N Engl J Med. 2021 Oct 20. doi: 10.1056/NEJMc2113864.
    PubMed    


  268. REIS BY, Barda N, Leshchinsky M, Kepten E, et al
    Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents.
    N Engl J Med. 2021 Oct 20. doi: 10.1056/NEJMc2114290.
    PubMed    


  269. NOLAN T, Fortanier AC, Leav B, Poder A, et al
    Efficacy of a Cell-Culture-Derived Quadrivalent Influenza Vaccine in Children.
    N Engl J Med. 2021;385:1485-1495.
    PubMed     Abstract available


  270. RUBIN EJ, Baden LR, Wu KJ, Morrissey S, et al
    Audio Interview: Reporting on Covid-19.
    N Engl J Med. 2021;385:e66.
    PubMed    


  271. HOCK H, Kelly HR, Meyerowitz EA, Frigault MJ, et al
    Case 31-2021: A 21-Year-Old Man with Sore Throat, Epistaxis, and Oropharyngeal Petechiae.
    N Engl J Med. 2021;385:1511-1520.
    PubMed    


  272. BALSARI S, Kiang MV, Buckee CO
    Data in Crisis - Rethinking Disaster Preparedness in the United States.
    N Engl J Med. 2021;385:1526-1530.
    PubMed    


  273. WHITE EM, Mor V
    SARS-CoV-2 Infection among Nursing Home Residents. Reply.
    N Engl J Med. 2021 Oct 13. pii: 10.1056/NEJMc2114113.
    PubMed    


  274. CHANDRASEKAR B
    SARS-CoV-2 Infection among Nursing Home Residents.
    N Engl J Med. 2021 Oct 13. pii: 10.1056/NEJMc2114113.
    PubMed    


  275. KORLEY FK, Durkalski-Mauldin V, Callaway CW
    Convalescent Plasma for Outpatients with Covid-19. Reply.
    N Engl J Med. 2021 Oct 13. pii: 10.1056/NEJMc2114591.
    PubMed    


  276. SCHULZ E
    Convalescent Plasma for Outpatients with Covid-19.
    N Engl J Med. 2021 Oct 13. pii: 10.1056/NEJMc2114591.
    PubMed    


  277. FISHER D, Malnick S
    Convalescent Plasma for Outpatients with Covid-19.
    N Engl J Med. 2021 Oct 13. pii: 10.1056/NEJMc2114591.
    PubMed    


  278. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Are Covid-19 Vaccine Boosters Necessary?
    N Engl J Med. 2021;385:e63.
    PubMed    


  279. THOMPSON MG, Grant L, Meece J
    Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. Reply.
    N Engl J Med. 2021 Oct 6. pii: 10.1056/NEJMc2113575.
    PubMed    


  280. ZHANG C, Yin G
    Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.
    N Engl J Med. 2021 Oct 6. pii: 10.1056/NEJMc2113575.
    PubMed    


  281. SCHOOLEY RT
    Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.
    N Engl J Med. 2021 Oct 6. pii: 10.1056/NEJMc2113575.
    PubMed    


  282. SANTACATTERINA M, Sanders JW, Weintraub WS
    Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.
    N Engl J Med. 2021 Oct 6. pii: 10.1056/NEJMc2113575.
    PubMed    


  283. O'BRIEN MP, Hou P, Weinreich DM
    Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. Reply.
    N Engl J Med. 2021 Oct 6. pii: 10.1056/NEJMc2113862.
    PubMed    


  284. MERISON T, Goldman A, Bomze D
    Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
    N Engl J Med. 2021 Oct 6. pii: 10.1056/NEJMc2113862.
    PubMed    


  285. WITBERG G, Barda N, Hoss S, Richter I, et al
    Myocarditis after Covid-19 Vaccination in a Large Health Care Organization.
    N Engl J Med. 2021 Oct 6. doi: 10.1056/NEJMoa2110737.
    PubMed     Abstract available


  286. MEVORACH D, Anis E, Cedar N, Bromberg M, et al
    Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel.
    N Engl J Med. 2021 Oct 6. doi: 10.1056/NEJMoa2109730.
    PubMed     Abstract available


  287. CHEMAITELLY H, Tang P, Hasan MR, AlMukdad S, et al
    Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.
    N Engl J Med. 2021 Oct 6. doi: 10.1056/NEJMoa2114114.
    PubMed     Abstract available


  288. LEVIN EG, Lustig Y, Cohen C, Fluss R, et al
    Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months.
    N Engl J Med. 2021 Oct 6. doi: 10.1056/NEJMoa2114583.
    PubMed     Abstract available


    September 2021
  289. RUBIN EJ, Baden LR, Tofel R, Morrissey S, et al
    Audio Interview: Covid-19 and the Media.
    N Engl J Med. 2021;385:e59.
    PubMed    


  290. RAPEPORT G, Chiu C, McShane H
    SARS-CoV-2 Human Challenge Studies. Reply.
    N Engl J Med. 2021 Sep 29. pii: 10.1056/NEJMc2113574.
    PubMed    


  291. STEUWER B, Eyal N
    SARS-CoV-2 Human Challenge Studies.
    N Engl J Med. 2021 Sep 29. pii: 10.1056/NEJMc2113574.
    PubMed    


  292. WEINREICH DM, Sivapalasingam S, Norton T, Ali S, et al
    REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.
    N Engl J Med. 2021 Sep 29. doi: 10.1056/NEJMoa2108163.
    PubMed     Abstract available


  293. FALSEY AR, Sobieszczyk ME, Hirsch I, Sproule S, et al
    Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
    N Engl J Med. 2021 Sep 29. doi: 10.1056/NEJMoa2105290.
    PubMed     Abstract available


  294. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Vaccine Efficacy and Boosters in Covid-19.
    N Engl J Med. 2021;385:e54.
    PubMed    


  295. ESSEX R, Weldon SM
    Health Care Worker Strikes and the Covid Pandemic. Reply.
    N Engl J Med. 2021;385:e43.
    PubMed    


  296. CHAN SSC
    Health Care Worker Strikes and the Covid Pandemic.
    N Engl J Med. 2021;385:e43.
    PubMed    


  297. SON MBF, Newburger JW, Randolph AG
    Therapy for Multisystem Inflammatory Syndrome in Children. Reply.
    N Engl J Med. 2021;385:e42.
    PubMed    


  298. MCARDLE AJ, Cunnington AJ, Levin M
    Therapy for Multisystem Inflammatory Syndrome in Children. Reply.
    N Engl J Med. 2021;385:e42.
    PubMed    


  299. OULDALI N, Belot A, Angoulvant F
    Therapy for Multisystem Inflammatory Syndrome in Children.
    N Engl J Med. 2021;385:e42.
    PubMed    


  300. HARLEY JB
    Therapy for Multisystem Inflammatory Syndrome in Children.
    N Engl J Med. 2021;385:e42.
    PubMed    


  301. EL SAHLY HM, Baden LR, Essink B, Doblecki-Lewis S, et al
    Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.
    N Engl J Med. 2021 Sep 22. doi: 10.1056/NEJMoa2113017.
    PubMed     Abstract available


  302. PILISHVILI T, Gierke R, Fleming-Dutra KE, Farrar JL, et al
    Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel.
    N Engl J Med. 2021 Sep 22. doi: 10.1056/NEJMoa2106599.
    PubMed     Abstract available


  303. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: New Evidence on SARS-CoV-2 Vaccine Boosters.
    N Engl J Med. 2021;385:e48.
    PubMed    


  304. NORTH CS, Sorg EM, Youn S, Chu JT, et al
    Case 28-2021: A 37-Year-Old Woman with Covid-19 and Suicidal Ideation.
    N Engl J Med. 2021;385:1125-1132.
    PubMed    


  305. FRENCK RW JR, Dormitzer PR, Gurtman A
    BNT162b2 Covid-19 Vaccine in Adolescents. Reply.
    N Engl J Med. 2021;385.
    PubMed    


  306. LIN CH
    BNT162b2 Covid-19 Vaccine in Adolescents.
    N Engl J Med. 2021;385.
    PubMed    


  307. JARA A, Undurraga EA, Araos R
    Effectiveness of an Inactivated SARS-CoV-2 Vaccine. Reply.
    N Engl J Med. 2021;385.
    PubMed    


  308. ONISHI FJ, Goto JM
    Effectiveness of an Inactivated SARS-CoV-2 Vaccine.
    N Engl J Med. 2021;385.
    PubMed    


  309. CHI H, Chiu NC, Lin CY
    Effectiveness of an Inactivated SARS-CoV-2 Vaccine.
    N Engl J Med. 2021;385.
    PubMed    


  310. OKHOTIN A
    Effectiveness of an Inactivated SARS-CoV-2 Vaccine.
    N Engl J Med. 2021;385.
    PubMed    


  311. BAR-ON YM, Goldberg Y, Mandel M, Bodenheimer O, et al
    Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel.
    N Engl J Med. 2021 Sep 15. doi: 10.1056/NEJMoa2114255.
    PubMed     Abstract available


  312. FALSEY AR, Frenck RW Jr, Walsh EE, Kitchin N, et al
    SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
    N Engl J Med. 2021 Sep 15. doi: 10.1056/NEJMc2113468.
    PubMed    


  313. THOMAS SJ, Moreira ED Jr, Kitchin N, Absalon J, et al
    Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.
    N Engl J Med. 2021 Sep 15. doi: 10.1056/NEJMoa2110345.
    PubMed     Abstract available


  314. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Protecting against Severe Disease and Transmission.
    N Engl J Med. 2021;385:e44.
    PubMed    


  315. MEANEY-DELMAN DM, Ellington SR, Shimabukuro TT
    On Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. Reply.
    N Engl J Med. 2021 Sep 8. pii: 10.1056/NEJMc2113516.
    PubMed    


  316. SUN H
    On Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons.
    N Engl J Med. 2021 Sep 8. pii: 10.1056/NEJMc2113516.
    PubMed    


  317. DEAN NE, Hogan JW, Schnitzer ME
    Covid-19 Vaccine Effectiveness and the Test-Negative Design.
    N Engl J Med. 2021 Sep 8. doi: 10.1056/NEJMe2113151.
    PubMed    


  318. THOMPSON MG, Stenehjem E, Grannis S, Ball SW, et al
    Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.
    N Engl J Med. 2021 Sep 8. doi: 10.1056/NEJMoa2110362.
    PubMed     Abstract available


  319. SHAH ASV, Gribben C, Bishop J, Hanlon P, et al
    Effect of Vaccination on Transmission of SARS-CoV-2.
    N Engl J Med. 2021 Sep 8. doi: 10.1056/NEJMc2106757.
    PubMed    


  320. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: A New Round of Rising Covid-19 Numbers.
    N Engl J Med. 2021;385:e41.
    PubMed    


  321. WILDER-SMITH A, Mulholland K
    Effectiveness of an Inactivated SARS-CoV-2 Vaccine.
    N Engl J Med. 2021;385:946-948.
    PubMed    


  322. WERNER RM, Glied SA
    Covid-Induced Changes in Health Care Delivery - Can They Last?
    N Engl J Med. 2021;385:868-870.
    PubMed    


  323. KEEHNER J, Horton LE, Binkin NJ, Laurent LC, et al
    Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce.
    N Engl J Med. 2021 Sep 1. doi: 10.1056/NEJMc2112981.
    PubMed    


  324. MELLO MM, Parmet WE
    Public Health Law after Covid-19.
    N Engl J Med. 2021 Sep 1. doi: 10.1056/NEJMp2112193.
    PubMed    


    August 2021
  325. LEVY JH, Connors JM
    Heparin Resistance - Clinical Perspectives and Management Strategies.
    N Engl J Med. 2021;385:826-832.
    PubMed    


  326. PAPINENI P
    A Pink Salwar.
    N Engl J Med. 2021;385:774-775.
    PubMed    


  327. LEE GM
    The Importance of Context in Covid-19 Vaccine Safety.
    N Engl J Med. 2021 Aug 25. doi: 10.1056/NEJMe2112543.
    PubMed    


  328. BARDA N, Dagan N, Ben-Shlomo Y, Kepten E, et al
    Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
    N Engl J Med. 2021 Aug 25. doi: 10.1056/NEJMoa2110475.
    PubMed     Abstract available


  329. UZUN G, Althaus K, Bakchoul T
    No Correlation between Anti-PF4 and Anti-SARS-CoV-2 Antibodies after ChAdOx1 nCoV-19 Vaccination.
    N Engl J Med. 2021 Aug 25. doi: 10.1056/NEJMc2111305.
    PubMed    


  330. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Aspects of Covid-19 Immunity.
    N Engl J Med. 2021;385:e31.
    PubMed    


  331. ROSAS IO, Raby B, Tsai L
    Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. Reply.
    N Engl J Med. 2021 Aug 18. pii: 10.1056/NEJMc2108482.
    PubMed    


  332. GORDON AC, Angus DC, Derde LPG
    Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. Reply.
    N Engl J Med. 2021 Aug 18. pii: 10.1056/NEJMc2108482.
    PubMed    


  333. BROWN MJ, Alazawi W, Kanoni S
    Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
    N Engl J Med. 2021 Aug 18. pii: 10.1056/NEJMc2108482.
    PubMed    


  334. TAN CW, Chia WN, Young BE, Zhu F, et al
    Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors.
    N Engl J Med. 2021 Aug 18. doi: 10.1056/NEJMoa2108453.
    PubMed     Abstract available


  335. KORLEY FK, Durkalski-Mauldin V, Yeatts SD, Schulman K, et al
    Early Convalescent Plasma for High-Risk Outpatients with Covid-19.
    N Engl J Med. 2021 Aug 18. doi: 10.1056/NEJMoa2103784.
    PubMed     Abstract available


  336. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Monoclonal Antibodies and Booster Shots.
    N Engl J Med. 2021;385:e29.
    PubMed    


  337. BARAS SHREIBATI J
    When Low Tech Wins.
    N Engl J Med. 2021;385:581-583.
    PubMed    


  338. PHILLIPS S, Williams MA
    Confronting Our Next National Health Disaster - Long-Haul Covid.
    N Engl J Med. 2021;385:577-579.
    PubMed    


  339. WILLIAMS WW, Ingelfinger JR
    Third Time's a Charm - Covid-19 Vaccine Hope for Solid-Organ Transplant Recipients.
    N Engl J Med. 2021 Aug 11. doi: 10.1056/NEJMe2112866.
    PubMed    


  340. PAVORD S, Scully M, Hunt BJ, Lester W, et al
    Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis.
    N Engl J Med. 2021 Aug 11. doi: 10.1056/NEJMoa2109908.
    PubMed     Abstract available


  341. ALI K, Berman G, Zhou H, Deng W, et al
    Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents.
    N Engl J Med. 2021 Aug 11. doi: 10.1056/NEJMoa2109522.
    PubMed     Abstract available


  342. HALL VG, Ferreira VH, Ku T, Ierullo M, et al
    Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.
    N Engl J Med. 2021 Aug 11. doi: 10.1056/NEJMc2111462.
    PubMed    


  343. COREY L, Beyrer C, Cohen MS, Michael NL, et al
    SARS-CoV-2 Variants in Patients with Immunosuppression.
    N Engl J Med. 2021;385:562-566.
    PubMed    


  344. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Looking Back and Looking Forward - Part 2.
    N Engl J Med. 2021;385:e25.
    PubMed    


  345. GOLIGHER EC, Bradbury CA, McVerry BJ, Lawler PR, et al
    Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
    N Engl J Med. 2021 Aug 4. doi: 10.1056/NEJMoa2103417.
    PubMed     Abstract available


  346. LAWLER PR, Goligher EC, Berger JS, Neal MD, et al
    Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
    N Engl J Med. 2021 Aug 4. doi: 10.1056/NEJMoa2105911.
    PubMed     Abstract available


  347. TEN CATE H
    Surviving Covid-19 with Heparin?
    N Engl J Med. 2021 Aug 4. doi: 10.1056/NEJMe2111151.
    PubMed    


  348. O'BRIEN MP, Forleo-Neto E, Musser BJ, Isa F, et al
    Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
    N Engl J Med. 2021 Aug 4. doi: 10.1056/NEJMoa2109682.
    PubMed     Abstract available


    July 2021
  349. GUIMARAES PO, Quirk D, Furtado RH, Maia LN, et al
    Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia.
    N Engl J Med. 2021;385:406-415.
    PubMed     Abstract available


  350. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Looking Back and Looking Forward - Part 1.
    N Engl J Med. 2021;385:e24.
    PubMed    


  351. BERGWERK M, Gonen T, Lustig Y, Amit S, et al
    Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.
    N Engl J Med. 2021 Jul 28. doi: 10.1056/NEJMoa2109072.
    PubMed     Abstract available


  352. RUBIN EJ, Baden LR, Armstrong KA, Morrissey S, et al
    Audio Interview: The Impact of Covid-19 on Trainees and Junior Faculty.
    N Engl J Med. 2021;385:e21.
    PubMed    


  353. MADHI SA, Izu A, Pollard AJ
    ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. Reply.
    N Engl J Med. 2021;385.
    PubMed    


  354. STRUYF F, Sadoff J, Douoguih M
    ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant.
    N Engl J Med. 2021;385.
    PubMed    


  355. LOPEZ BERNAL J, Andrews N, Gower C, Gallagher E, et al
    Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
    N Engl J Med. 2021 Jul 21. doi: 10.1056/NEJMoa2108891.
    PubMed     Abstract available


  356. RAPEPORT G, Smith E, Gilbert A, Catchpole A, et al
    SARS-CoV-2 Human Challenge Studies - Establishing the Model during an Evolving Pandemic.
    N Engl J Med. 2021 Jul 21. doi: 10.1056/NEJMp2106970.
    PubMed    


  357. CHU VT, Yousaf AR, Chang K, Schwartz NG, et al
    Household Transmission of SARS-CoV-2 from Children and Adolescents.
    N Engl J Med. 2021 Jul 21. doi: 10.1056/NEJMc2031915.
    PubMed    


  358. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Monoclonal Antibodies and Vaccine Boosts.
    N Engl J Med. 2021;385:e18.
    PubMed    


  359. NORMARK J, Vikstrom L, Gwon YD, Persson IL, et al
    Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination.
    N Engl J Med. 2021 Jul 14. doi: 10.1056/NEJMc2110716.
    PubMed    


  360. DOUGAN M, Nirula A, Azizad M, Mocherla B, et al
    Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.
    N Engl J Med. 2021 Jul 14. doi: 10.1056/NEJMoa2102685.
    PubMed     Abstract available


  361. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: How Well Are Covid-19 Vaccines Working?
    N Engl J Med. 2021;385:e15.
    PubMed    


  362. EDARA VV, Pinsky BA, Suthar MS, Lai L, et al
    Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants.
    N Engl J Med. 2021 Jul 7. doi: 10.1056/NEJMc2107799.
    PubMed    


  363. BRINKLEY-RUBINSTEIN L, Peterson M, Martin R, Chan P, et al
    Breakthrough SARS-CoV-2 Infections in Prison after Vaccination.
    N Engl J Med. 2021 Jul 7. doi: 10.1056/NEJMc2108479.
    PubMed    


  364. JARA A, Undurraga EA, Gonzalez C, Paredes F, et al
    Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile.
    N Engl J Med. 2021 Jul 7. doi: 10.1056/NEJMoa2107715.
    PubMed     Abstract available


  365. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Another New Covid-19 Vaccine.
    N Engl J Med. 2021;385:e13.
    PubMed    


  366. SON MBF, Murray N, Friedman K, Young CC, et al
    Multisystem Inflammatory Syndrome in Children - Initial Therapy and Outcomes.
    N Engl J Med. 2021;385:23-34.
    PubMed     Abstract available


  367. MCARDLE AJ, Vito O, Patel H, Seaby EG, et al
    Treatment of Multisystem Inflammatory Syndrome in Children.
    N Engl J Med. 2021;385:11-22.
    PubMed     Abstract available


    June 2021
  368. THOMPSON MG, Burgess JL, Naleway AL, Tyner H, et al
    Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.
    N Engl J Med. 2021 Jun 30. doi: 10.1056/NEJMoa2107058.
    PubMed     Abstract available


  369. HEATH PT, Galiza EP, Baxter DN, Boffito M, et al
    Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.
    N Engl J Med. 2021 Jun 30. doi: 10.1056/NEJMoa2107659.
    PubMed     Abstract available


  370. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: A New mRNA Vaccine.
    N Engl J Med. 2021;384:e109.
    PubMed    


  371. KRAUSE PR, Fleming TR, Longini IM, Peto R, et al
    SARS-CoV-2 Variants and Vaccines.
    N Engl J Med. 2021 Jun 23. doi: 10.1056/NEJMsr2105280.
    PubMed     Abstract available


  372. KAMAR N, Abravanel F, Marion O, Couat C, et al
    Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.
    N Engl J Med. 2021 Jun 23. doi: 10.1056/NEJMc2108861.
    PubMed    


  373. HARRIS RJ, Hall JA, Zaidi A, Andrews NJ, et al
    Effect of Vaccination on Household Transmission of SARS-CoV-2 in England.
    N Engl J Med. 2021 Jun 23. doi: 10.1056/NEJMc2107717.
    PubMed    


  374. KOENIG PA, Schmidt FI
    Spike D614G - A Candidate Vaccine Antigen Against Covid-19.
    N Engl J Med. 2021;384:2349-2351.
    PubMed    


  375. RILEY LE
    mRNA Covid-19 Vaccines in Pregnant Women.
    N Engl J Med. 2021;384:2342-2343.
    PubMed    


  376. JAGSI R, Fuentes-Afflick E, Higginbotham E
    Promoting Equity for Women in Medicine - Seizing a Disruptive Opportunity.
    N Engl J Med. 2021;384:2265-2267.
    PubMed    


  377. HIBBERT KA, Goiffon RJ, Fogerty AE
    Case 18-2021: An 81-Year-Old Man with Cough, Fever, and Shortness of Breath.
    N Engl J Med. 2021;384:2332-2340.
    PubMed    


  378. ESSEX R, Weldon SM
    Health Care Worker Strikes and the Covid Pandemic.
    N Engl J Med. 2021;384:e93.
    PubMed    


  379. RUBIN EJ, Baden LR, Ingelfinger JR, Morrissey S, et al
    Audio Interview: Covid-19 in Children.
    N Engl J Med. 2021;384:e108.
    PubMed    


  380. VANDEBOSCH A, Sadoff J, Douoguih M
    Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. Reply.
    N Engl J Med. 2021 Jun 9. pii: 10.1056/NEJMc2107809.
    PubMed    


  381. HEININGER U
    Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
    N Engl J Med. 2021 Jun 9. pii: 10.1056/NEJMc2107809.
    PubMed    


  382. SAMARAKOON U, Alvarez-Arango S, Blumenthal KG
    Delayed Large Local Reactions to mRNA Covid-19 Vaccines in Blacks, Indigenous Persons, and People of Color.
    N Engl J Med. 2021 Jun 9. doi: 10.1056/NEJMc2108620.
    PubMed    


  383. BECKER SJ, Taylor J, Sharfstein JM
    Identifying and Tracking SARS-CoV-2 Variants - A Challenge and an Opportunity.
    N Engl J Med. 2021 Jun 9. doi: 10.1056/NEJMp2103859.
    PubMed    


  384. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Vaccinating Children.
    N Engl J Med. 2021;384:e103.
    PubMed    


  385. BLACHERE NE, Hacisuleyman E, Darnell RB
    Vaccine Breakthrough Infections with SARS-CoV-2 Variants. Reply.
    N Engl J Med. 2021 Jun 2. pii: 10.1056/NEJMc2107808.
    PubMed    


  386. RANA K, Mohindra R, Pinnaka L
    Vaccine Breakthrough Infections with SARS-CoV-2 Variants.
    N Engl J Med. 2021 Jun 2. pii: 10.1056/NEJMc2107808.
    PubMed    


  387. NIXON DF, Ndhlovu LC
    Vaccine Breakthrough Infections with SARS-CoV-2 Variants.
    N Engl J Med. 2021 Jun 2. pii: 10.1056/NEJMc2107808.
    PubMed    


    May 2021
  388. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Protecting the Immunosuppressed against Covid-19.
    N Engl J Med. 2021;384:e88.
    PubMed    


  389. BURRIS S, Anderson ED, Wagenaar AC
    The "Legal Epidemiology" of Pandemic Control.
    N Engl J Med. 2021;384:1973-1975.
    PubMed    


  390. FRENCK RW JR, Klein NP, Kitchin N, Gurtman A, et al
    Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
    N Engl J Med. 2021 May 27. doi: 10.1056/NEJMoa2107456.
    PubMed     Abstract available


  391. VOLPP KG, Cannuscio CC
    Incentives for Immunity - Strategies for Increasing Covid-19 Vaccine Uptake.
    N Engl J Med. 2021 May 26. doi: 10.1056/NEJMp2107719.
    PubMed    


  392. SPARROW AK, Brosseau LM, Harrison RJ, Osterholm MT, et al
    Protecting Olympic Participants from Covid-19 - The Urgent Need for a Risk-Management Approach.
    N Engl J Med. 2021 May 25. doi: 10.1056/NEJMp2108567.
    PubMed    


  393. RUBIN EJ, Baden LR, Drazen JM, Taichman DB, et al
    Audio Interview: Vaccination in Nursing Homes and New Pulmonary/Critical Care Research.
    N Engl J Med. 2021;384:e89.
    PubMed    


  394. O'CONNELL J, O'Keeffe DT
    Contact Tracing for Covid-19 - A Digital Inoculation against Future Pandemics.
    N Engl J Med. 2021 May 19. doi: 10.1056/NEJMp2102256.
    PubMed    


  395. WHITE EM, Yang X, Blackman C, Feifer RA, et al
    Incident SARS-CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home Residents.
    N Engl J Med. 2021 May 19. doi: 10.1056/NEJMc2104849.
    PubMed    


  396. RUBIN EJ, Baden LR, Gray GE, Morrissey S, et al
    Audio Interview: Vaccination and Variants in the U.S. and South Africa.
    N Engl J Med. 2021;384:e85.
    PubMed    


  397. RODRIGUEZ-HERNANDEZ M, Pilato TC, Yerdon KA, Kysel IM, et al
    Detained.
    N Engl J Med. 2021;384:1785-1787.
    PubMed    


  398. WAPPNER D, Bergel E, Polack FP
    Plasma Therapy to Prevent Severe Covid-19 in Older Adults. Reply.
    N Engl J Med. 2021 May 12. pii: 10.1056/NEJMc2104747.
    PubMed    


  399. RAGUSA M, Tortosa F, Izcovich A
    Plasma Therapy to Prevent Severe Covid-19 in Older Adults.
    N Engl J Med. 2021 May 12. pii: 10.1056/NEJMc2104747.
    PubMed    


  400. KLAMT F, Parsons RB, Jones MH
    Plasma Therapy to Prevent Severe Covid-19 in Older Adults.
    N Engl J Med. 2021 May 12. pii: 10.1056/NEJMc2104747.
    PubMed    


  401. KEEHNER J, Abeles SR, Torriani FJ
    More on SARS-CoV-2 Infection after Vaccination in Health Care Workers. Reply.
    N Engl J Med. 2021 May 12. pii: 10.1056/NEJMc2106004.
    PubMed    


  402. LIU Y, Liu J, Xia H, Zhang X, et al
    BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants.
    N Engl J Med. 2021 May 12. doi: 10.1056/NEJMc2106083.
    PubMed    


  403. SCALES D, Gorman J, Jamieson KH
    The Covid-19 Infodemic - Applying the Epidemiologic Model to Counter Misinformation.
    N Engl J Med. 2021 May 12. doi: 10.1056/NEJMp2103798.
    PubMed    


  404. RUBIN EJ, Baden LR, Udwadia ZF, Morrissey S, et al
    Audio Interview: India's Covid-19 Crisis.
    N Engl J Med. 2021;384:e84.
    PubMed    


  405. SALWA J, Robertson C
    Designing an Independent Public Health Agency.
    N Engl J Med. 2021;384:1684-1687.
    PubMed    


  406. NEUZIL KM
    Interplay between Emerging SARS-CoV-2 Variants and Pandemic Control.
    N Engl J Med. 2021 May 5. doi: 10.1056/NEJMe2103931.
    PubMed    


  407. SHINDE V, Bhikha S, Hoosain Z, Archary M, et al
    Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
    N Engl J Med. 2021 May 5. doi: 10.1056/NEJMoa2103055.
    PubMed     Abstract available


  408. RATZAN S, Schneider EC, Hatch H, Cacchione J, et al
    Missing the Point - How Primary Care Can Overcome Covid-19 Vaccine "Hesitancy".
    N Engl J Med. 2021 May 5. doi: 10.1056/NEJMp2106137.
    PubMed    


  409. ABU-RADDAD LJ, Chemaitelly H, Butt AA
    Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.
    N Engl J Med. 2021 May 5. doi: 10.1056/NEJMc2104974.
    PubMed    


    April 2021
  410. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Advice for Clinicians on Covid-19 Vaccines and Social Restrictions.
    N Engl J Med. 2021;384:e77.
    PubMed    


  411. KADAKIA KT, Beckman AL, Ross JS, Krumholz HM, et al
    Leveraging Open Science to Accelerate Research.
    N Engl J Med. 2021;384:e61.
    PubMed    


  412. GOLDFARB JL, Kreps S, Brownstein JS, Kriner DL, et al
    Beyond the First Dose - Covid-19 Vaccine Follow-through and Continued Protective Measures.
    N Engl J Med. 2021 Apr 28. doi: 10.1056/NEJMp2104527.
    PubMed    


  413. FAJGENBAUM DC, June CH
    Cytokine Storm. Reply.
    N Engl J Med. 2021;384:e59.
    PubMed    


  414. MUDD PA, Crawford JC, Thomas PG
    Cytokine Storm.
    N Engl J Med. 2021;384:e59.
    PubMed    


  415. SUPADY A, Bode C, Duerschmied D
    Cytokine Storm.
    N Engl J Med. 2021;384:e59.
    PubMed    


  416. GAESTEL M, Nebreda AR, Yaffe MB
    Cytokine Storm.
    N Engl J Med. 2021;384:e59.
    PubMed    


  417. RUBIN EJ, Baden LR, Walensky RP, Morrissey S, et al
    Audio Interview: Covid-19 Vaccines and Pregnancy - A Conversation with CDC Director Rochelle Walensky.
    N Engl J Med. 2021;384:e73.
    PubMed    


  418. DODD LE, Freidlin B, Korn EL
    Platform Trials - Beware the Noncomparable Control Group.
    N Engl J Med. 2021;384:1572-1573.
    PubMed    


  419. CANELLI R, Shrestha GS, Ortega R
    Emergency Intubation in Covid-19. Reply.
    N Engl J Med. 2021;384.
    PubMed    


  420. PATEL J, Janapala RN, Pourmand A
    Emergency Intubation in Covid-19.
    N Engl J Med. 2021;384.
    PubMed    


  421. SELLERS WFS
    Emergency Intubation in Covid-19.
    N Engl J Med. 2021;384.
    PubMed    


  422. HERZOG N, Giacardi C, Danguy des Deserts M
    Emergency Intubation in Covid-19.
    N Engl J Med. 2021;384.
    PubMed    


  423. BARDA N, Dagan N, Balicer RD
    BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. Reply.
    N Engl J Med. 2021;384.
    PubMed    


  424. ROEST S, Hoek RAS, Manintveld OC
    BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
    N Engl J Med. 2021;384.
    PubMed    


  425. BAECK M, Marot L, Belkhir L
    Delayed Large Local Reactions to mRNA Vaccines.
    N Engl J Med. 2021 Apr 21. pii: 10.1056/NEJMc2104751.
    PubMed    


  426. SADOFF J, Gray G, Vandebosch A, Cardenas V, et al
    Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
    N Engl J Med. 2021 Apr 21. doi: 10.1056/NEJMoa2101544.
    PubMed     Abstract available


  427. HACISULEYMAN E, Hale C, Saito Y, Blachere NE, et al
    Vaccine Breakthrough Infections with SARS-CoV-2 Variants.
    N Engl J Med. 2021 Apr 21. doi: 10.1056/NEJMoa2105000.
    PubMed     Abstract available


  428. CINES DB, Bussel JB
    SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia.
    N Engl J Med. 2021 Apr 16. doi: 10.1056/NEJMe2106315.
    PubMed    


  429. SCULLY M, Singh D, Lown R, Poles A, et al
    Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination.
    N Engl J Med. 2021 Apr 16. doi: 10.1056/NEJMoa2105385.
    PubMed     Abstract available


  430. MECKLAI K, Smith N, Stern AD, Kramer DB, et al
    Remote Patient Monitoring - Overdue or Overused?
    N Engl J Med. 2021;384:1384-1386.
    PubMed    


  431. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Vaccine Successes and Vaccine Adverse Events.
    N Engl J Med. 2021;384:e70.
    PubMed    


  432. LIU Y, Liu J, Xia H, Zhang X, et al
    Neutralizing Activity of BNT162b2-Elicited Serum.
    N Engl J Med. 2021;384:1466-1468.
    PubMed    


  433. ANICHINI G, Terrosi C, Gandolfo C, Gori Savellini G, et al
    SARS-CoV-2 Antibody Response in Persons with Past Natural Infection.
    N Engl J Med. 2021 Apr 14. doi: 10.1056/NEJMc2103825.
    PubMed    


  434. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Antibody Responses to Natural Infection and Vaccination.
    N Engl J Med. 2021;384:e65.
    PubMed    


  435. SASISEKHARAN R
    Preparing for the Future - Nanobodies for Covid-19?
    N Engl J Med. 2021 Apr 7. doi: 10.1056/NEJMcibr2101205.
    PubMed    


  436. MOYO-GWETE T, Madzivhandila M, Makhado Z, Ayres F, et al
    Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).
    N Engl J Med. 2021 Apr 7. doi: 10.1056/NEJMc2104192.
    PubMed    


  437. LUSTIG Y, Nemet I, Kliker L, Zuckerman N, et al
    Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2.
    N Engl J Med. 2021 Apr 7. doi: 10.1056/NEJMc2104036.
    PubMed    


  438. SHEN X, Tang H, Pajon R, Smith G, et al
    Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351.
    N Engl J Med. 2021 Apr 7. doi: 10.1056/NEJMc2103740.
    PubMed    


  439. KIM MC, Park MS, Chung JW
    Viable SARS-CoV-2 Shedding. Reply.
    N Engl J Med. 2021;384.
    PubMed    


  440. ROMANO CM, Felix AC, Pannuti CS
    Viable SARS-CoV-2 Shedding.
    N Engl J Med. 2021;384.
    PubMed    


  441. DORIA-ROSE N, Suthar MS, Makowski M, O'Connell S, et al
    Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.
    N Engl J Med. 2021 Apr 6. doi: 10.1056/NEJMc2103916.
    PubMed    


  442. WANG GL, Wang ZY, Duan LJ, Meng QC, et al
    Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization.
    N Engl J Med. 2021 Apr 6. doi: 10.1056/NEJMc2103022.
    PubMed    


  443. ELIAS C, Nkengasong JN, Qadri F
    Emerging Infectious Diseases - Learning from the Past and Looking to the Future.
    N Engl J Med. 2021;384:1181-1184.
    PubMed    


  444. RUBIN EJ, Baden LR, Del Rio C, Akusobi C, et al
    Audio Interview: Delivering Covid-19 Vaccines to Minority Communities.
    N Engl J Med. 2021;384:e60.
    PubMed    


    March 2021
  445. QUINN SC, Andrasik MP
    Addressing Vaccine Hesitancy in BIPOC Communities - Toward Trustworthiness, Partnership, and Reciprocity.
    N Engl J Med. 2021 Mar 31. doi: 10.1056/NEJMp2103104.
    PubMed    


  446. NACHEGA JB, Sam-Agudu NA, Mellors JW, Zumla A, et al
    Scaling Up Covid-19 Vaccination in Africa - Lessons from the HIV Pandemic.
    N Engl J Med. 2021 Mar 31. doi: 10.1056/NEJMp2103313.
    PubMed    


  447. HALL MA, Studdert DM
    "Vaccine Passport" Certification - Policy and Ethical Considerations.
    N Engl J Med. 2021 Mar 31. doi: 10.1056/NEJMp2104289.
    PubMed    


  448. RUBIN EJ, Baden LR, Brandt AM, Morrissey S, et al
    Audio Interview: What Earlier Epidemics Teach Us about Covid-19.
    N Engl J Med. 2021;384:e55.
    PubMed    


  449. KADIRE SR, Fabre V, Wenzel RP
    Doctor, How Long Should I Isolate?
    N Engl J Med. 2021;384:e47.
    PubMed    


  450. ONI-ORISAN A, Mavura Y, Banda Y, Thornton TA, et al
    Embracing Genetic Diversity to Improve Black Health.
    N Engl J Med. 2021;384:1163-1167.
    PubMed    


  451. ABDOOL KARIM SS, de Oliveira T
    New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications.
    N Engl J Med. 2021 Mar 24. doi: 10.1056/NEJMc2100362.
    PubMed    


  452. ARMSTRONG K
    Covid-19 and the Investigator Pipeline.
    N Engl J Med. 2021 Mar 24. doi: 10.1056/NEJMp2100086.
    PubMed    


  453. KEEHNER J, Horton LE, Pfeffer MA, Longhurst CA, et al
    SARS-CoV-2 Infection after Vaccination in Health Care Workers in California.
    N Engl J Med. 2021 Mar 23. doi: 10.1056/NEJMc2101927.
    PubMed    


  454. BENENSON S, Oster Y, Cohen MJ, Nir-Paz R, et al
    BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers.
    N Engl J Med. 2021 Mar 23. doi: 10.1056/NEJMc2101951.
    PubMed    


  455. DANIEL W, Nivet M, Warner J, Podolsky DK, et al
    Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center.
    N Engl J Med. 2021 Mar 23. doi: 10.1056/NEJMc2102153.
    PubMed    


  456. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Efficacy of Current Covid-19 Vaccines against Variant Viruses.
    N Engl J Med. 2021;384:e53.
    PubMed    


  457. WU K, Werner AP, Koch M, Choi A, et al
    Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.
    N Engl J Med. 2021 Mar 17. doi: 10.1056/NEJMc2102179.
    PubMed    


  458. KRUTIKOV M, Hayward A, Shallcross L
    Spread of a Variant SARS-CoV-2 in Long-Term Care Facilities in England.
    N Engl J Med. 2021 Mar 16. doi: 10.1056/NEJMc2035906.
    PubMed    


  459. MADHI SA, Baillie V, Cutland CL, Voysey M, et al
    Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
    N Engl J Med. 2021 Mar 16. doi: 10.1056/NEJMoa2102214.
    PubMed     Abstract available


  460. CARTER S
    Breathless.
    N Engl J Med. 2021;384:891-893.
    PubMed    


  461. RUBIN EJ, Baden LR, Abraham J, Morrissey S, et al
    Audio Interview: The Implications of Changes in the Structural Biology of SARS-CoV-2.
    N Engl J Med. 2021;384:e48.
    PubMed    


  462. POOLE MK, Fleischhacker SE, Bleich SN
    Addressing Child Hunger When School Is Closed - Considerations during the Pandemic and Beyond.
    N Engl J Med. 2021;384:e35.
    PubMed    


  463. KRAMMER F, Srivastava K, Alshammary H, Amoako AA, et al
    Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.
    N Engl J Med. 2021 Mar 10. doi: 10.1056/NEJMc2101667.
    PubMed    


  464. GORALNICK E, Kaufmann C, Gawande AA
    Mass-Vaccination Sites - An Essential Innovation to Curb the Covid-19 Pandemic.
    N Engl J Med. 2021 Mar 10. doi: 10.1056/NEJMp2102535.
    PubMed    


  465. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: A New SARS-CoV-2 Vaccine and a New Look at Treatment.
    N Engl J Med. 2021;384:e46.
    PubMed    


  466. GOLETTI D, Cantini F
    Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled.
    N Engl J Med. 2021;384:867-869.
    PubMed    


  467. BLUMENTHAL KG, Freeman EE, Saff RR, Robinson LB, et al
    Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2.
    N Engl J Med. 2021 Mar 3. doi: 10.1056/NEJMc2102131.
    PubMed    


  468. STONE JH
    Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. Reply.
    N Engl J Med. 2021 Mar 3. pii: 10.1056/NEJMc2100217.
    PubMed    


  469. SALAMA C, Mohan SV
    Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. Reply.
    N Engl J Med. 2021 Mar 3. pii: 10.1056/NEJMc2100217.
    PubMed    


  470. LUNDH A
    Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.
    N Engl J Med. 2021 Mar 3. pii: 10.1056/NEJMc2100217.
    PubMed    


  471. STEELFISHER GK, Blendon RJ, Caporello H
    An Uncertain Public - Encouraging Acceptance of Covid-19 Vaccines.
    N Engl J Med. 2021 Mar 3. doi: 10.1056/NEJMp2100351.
    PubMed    


  472. BARSKY BA, Reinhart E, Farmer P, Keshavjee S, et al
    Vaccination plus Decarceration - Stopping Covid-19 in Jails and Prisons.
    N Engl J Med. 2021 Mar 3. doi: 10.1056/NEJMp2100609.
    PubMed    


  473. KRAMER DB, Opel DJ, Parasidis E, Mello MM, et al
    Choices in a Crisis - Individual Preferences among SARS-CoV-2 Vaccines.
    N Engl J Med. 2021 Mar 3. doi: 10.1056/NEJMp2102146.
    PubMed    


  474. LUDVIGSSON JF
    Open Schools, Covid-19, and Child and Teacher Morbidity in Sweden. Reply.
    N Engl J Med. 2021 Mar 1. pii: 10.1056/NEJMc2101280.
    PubMed    


  475. BESANCON L, Steadson D, Flahault A
    Open Schools, Covid-19, and Child and Teacher Morbidity in Sweden.
    N Engl J Med. 2021 Mar 1. pii: 10.1056/NEJMc2101280.
    PubMed    


  476. TAKEFUJI Y
    Open Schools, Covid-19, and Child and Teacher Morbidity in Sweden.
    N Engl J Med. 2021 Mar 1. pii: 10.1056/NEJMc2101280.
    PubMed    


    February 2021
  477. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: The Real-World Effectiveness of Covid-19 Vaccination.
    N Engl J Med. 2021;384:e40.
    PubMed    


  478. NORMAND ST
    The RECOVERY Platform.
    N Engl J Med. 2021;384:757-758.
    PubMed    


  479. LANE HC, Fauci AS
    Research in the Context of a Pandemic.
    N Engl J Med. 2021;384:755-757.
    PubMed    


  480. MEHROTRA A, Nimgaonkar A, Richman B
    Telemedicine and Medical Licensure - Potential Paths for Reform.
    N Engl J Med. 2021;384:687-690.
    PubMed    


  481. VAIS S
    The Inequity of Isolation.
    N Engl J Med. 2021;384:690-691.
    PubMed    


  482. ROSAS IO, Brau N, Waters M, Go RC, et al
    Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.
    N Engl J Med. 2021 Feb 25. doi: 10.1056/NEJMoa2028700.
    PubMed     Abstract available


  483. GORDON AC, Mouncey PR, Al-Beidh F, Rowan KM, et al
    Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
    N Engl J Med. 2021 Feb 25. doi: 10.1056/NEJMoa2100433.
    PubMed     Abstract available


  484. RUBIN EJ, Longo DL, Baden LR
    Interleukin-6 Receptor Inhibition in Covid-19 - Cooling the Inflammatory Soup.
    N Engl J Med. 2021 Feb 25. doi: 10.1056/NEJMe2103108.
    PubMed    


  485. DAGAN N, Barda N, Kepten E, Miron O, et al
    BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
    N Engl J Med. 2021 Feb 24. doi: 10.1056/NEJMoa2101765.
    PubMed     Abstract available


  486. RUBIN EJ, Baden LR, Farrar JJ, Morrissey S, et al
    Audio Interview: Viral Variants and Covid-19.
    N Engl J Med. 2021;384:e38.
    PubMed    


  487. SHRESTHA GS, Shrestha N, Lamsal R, Pradhan S, et al
    Emergency Intubation in Covid-19.
    N Engl J Med. 2021;384:e20.
    PubMed    


  488. KADIRE SR, Wachter RM, Lurie N
    Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination.
    N Engl J Med. 2021 Feb 17. doi: 10.1056/NEJMclde2101987.
    PubMed    


  489. ABSALON J, Koury K, Gruber WC
    Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply.
    N Engl J Med. 2021;384.
    PubMed    


  490. WANG X
    Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
    N Engl J Med. 2021;384.
    PubMed    


  491. VERGNES JN
    Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
    N Engl J Med. 2021;384.
    PubMed    


  492. SKOWRONSKI DM, De Serres G
    Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
    N Engl J Med. 2021;384.
    PubMed    


  493. ROSENBAUM L
    Escaping Catch-22 - Overcoming Covid Vaccine Hesitancy.
    N Engl J Med. 2021 Feb 12. doi: 10.1056/NEJMms2101220.
    PubMed    


  494. HARRINGTON DP, Baden LR, Hogan JW
    A Large, Simple Trial Leading to Complex Questions.
    N Engl J Med. 2021;384:576-577.
    PubMed    


  495. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Does Vaccination Mean the End of Masking and Social Distancing?
    N Engl J Med. 2021;384:e32.
    PubMed    


  496. HORBY P, White NJ, Landray MJ
    Hydroxychloroquine in Hospitalized Patients with Covid-19. Reply.
    N Engl J Med. 2021;384.
    PubMed    


  497. LACOUT A, Perronne C, Lounnas V
    Hydroxychloroquine in Hospitalized Patients with Covid-19.
    N Engl J Med. 2021;384.
    PubMed    


  498. CASTELLS MC, Phillips EJ
    Maintaining Safety with SARS-CoV-2 Vaccines. Reply.
    N Engl J Med. 2021 Feb 10. pii: 10.1056/NEJMc2100766.
    PubMed    


  499. ROLLA G, Brussino L, Badiu I
    Maintaining Safety with SARS-CoV-2 Vaccines.
    N Engl J Med. 2021 Feb 10. pii: 10.1056/NEJMc2100766.
    PubMed    


  500. KASPER MR, Geibe JR
    An Outbreak of Covid-19 on an Aircraft Carrier. Reply.
    N Engl J Med. 2021;384.
    PubMed    


  501. BYLICKI O, Paleiron N, Janvier F
    An Outbreak of Covid-19 on an Aircraft Carrier.
    N Engl J Med. 2021;384.
    PubMed    


  502. RUBIN EJ, Baden LR, Northam RS, Morrissey S, et al
    Audio Interview: Covid-19 and the States - A Conversation with Ralph Northam.
    N Engl J Med. 2021;384:e25.
    PubMed    


  503. WYLLIE AL, Vogels CBF, Grubaugh ND
    Saliva for Detection of SARS-CoV-2. Reply.
    N Engl J Med. 2021;384.
    PubMed    


  504. MARKEWITZ RDH, Wandinger KP, Junker R
    Saliva for Detection of SARS-CoV-2.
    N Engl J Med. 2021;384.
    PubMed    


  505. LUNDGREN JD, Lane HC, Neaton JD
    Monoclonal Antibody for Patients with Covid-19. Reply.
    N Engl J Med. 2021 Feb 3. pii: 10.1056/NEJMc2100221.
    PubMed    


  506. JAWORSKI JP
    Monoclonal Antibody for Patients with Covid-19.
    N Engl J Med. 2021 Feb 3. pii: 10.1056/NEJMc2100221.
    PubMed    


    January 2021
  507. RUBIN EJ, Baden LR, Fauci AS, Morrissey S, et al
    Audio Interview: A Covid-19 Conversation with Anthony Fauci.
    N Engl J Med. 2021;384:e22.
    PubMed    


  508. HEATON PM
    The Covid-19 Vaccine-Development Multiverse. Reply.
    N Engl J Med. 2021;384.
    PubMed    


  509. KOJIMA N, Turner I, Klausner JD
    The Covid-19 Vaccine-Development Multiverse.
    N Engl J Med. 2021;384.
    PubMed    


  510. KIM MC, Cui C, Shin KR, Bae JY, et al
    Duration of Culturable SARS-CoV-2 in Hospitalized Patients with Covid-19.
    N Engl J Med. 2021 Jan 27. doi: 10.1056/NEJMc2027040.
    PubMed    


  511. LEE TH, Chen AH
    Last-Mile Logistics of Covid Vaccination - The Role of Health Care Organizations.
    N Engl J Med. 2021 Jan 27. doi: 10.1056/NEJMp2100574.
    PubMed    


  512. COHEN MS
    Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection.
    N Engl J Med. 2021;384:289-291.
    PubMed    


  513. BOTTI-LODOVICO Y, Rosenberg E, Sabeti PC
    Testing in a Pandemic - Improving Access, Coordination, and Prioritization.
    N Engl J Med. 2021;384:197-199.
    PubMed    


  514. RUBIN EJ, Baden LR, Nottage K, O'Connell J, et al
    Audio Interview: An International Look at Covid-19.
    N Engl J Med. 2021;384:e19.
    PubMed    


  515. PARMET WE
    Roman Catholic Diocese of Brooklyn v. Cuomo - The Supreme Court and Pandemic Controls.
    N Engl J Med. 2021;384:199-201.
    PubMed    


  516. KLASS P, Ratner AJ
    Vaccinating Children against Covid-19 - The Lessons of Measles.
    N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMp2034765.
    PubMed    


  517. VAN TASSEL K, Shachar C, Hoffman S
    Covid-19 Vaccine Injuries - Preventing Inequities in Compensation.
    N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMp2034438.
    PubMed    


  518. RUBIN EJ, Baden LR, Abdool Karim SS, Morrissey S, et al
    Audio Interview: Covid-19 in South Africa and a New SARS-CoV-2 Variant.
    N Engl J Med. 2021;384:e14.
    PubMed    


  519. KATZ LM
    (A Little) Clarity on Convalescent Plasma for Covid-19.
    N Engl J Med. 2021 Jan 13. doi: 10.1056/NEJMe2035678.
    PubMed    


  520. JOYNER MJ, Carter RE, Senefeld JW, Klassen SA, et al
    Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.
    N Engl J Med. 2021 Jan 13. doi: 10.1056/NEJMoa2031893.
    PubMed     Abstract available


  521. SADOFF J, Le Gars M, Shukarev G, Heerwegh D, et al
    Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
    N Engl J Med. 2021 Jan 13. doi: 10.1056/NEJMoa2034201.
    PubMed     Abstract available


  522. RUBIN EJ, Baden LR, Lee TH, Morrissey S, et al
    Audio Interview: Planning for the SARS-CoV-2 Vaccine Rollout.
    N Engl J Med. 2021;384:e13.
    PubMed    


  523. LIBSTER R, Perez Marc G, Wappner D, Coviello S, et al
    Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.
    N Engl J Med. 2021 Jan 6. doi: 10.1056/NEJMoa2033700.
    PubMed     Abstract available


  524. LUDVIGSSON JF, Engerstrom L, Nordenhall C, Larsson E, et al
    Open Schools, Covid-19, and Child and Teacher Morbidity in Sweden.
    N Engl J Med. 2021 Jan 6. doi: 10.1056/NEJMc2026670.
    PubMed    


  525. WOOD S, Schulman K
    Beyond Politics - Promoting Covid-19 Vaccination in the United States.
    N Engl J Med. 2021 Jan 6. doi: 10.1056/NEJMms2033790.
    PubMed    


    December 2020
  526. MILLER SE
    Visualization of SARS-CoV-2 in the Lung.
    N Engl J Med. 2020;383:2689.
    PubMed    


  527. ACKERMANN M, Mentzer SJ, Jonigk D
    Visualization of SARS-CoV-2 in the Lung. Reply.
    N Engl J Med. 2020;383:2689-2690.
    PubMed    


  528. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: A Look at Covid-19 Prevention and Care in 2020.
    N Engl J Med. 2020;383:e147.
    PubMed    


  529. PERRIN JM, Kenney GM, Rosenbaum S
    Medicaid and Child Health Equity.
    N Engl J Med. 2020;383:2595-2598.
    PubMed    


  530. CHATTERJEE P, Sommers BD, Joynt Maddox KE
    Essential but Undefined - Reimagining How Policymakers Identify Safety-Net Hospitals.
    N Engl J Med. 2020;383:2593-2595.
    PubMed    


  531. RUBIN D, Chan-Tack K, Farley J, Sherwat A, et al
    FDA Approval of Remdesivir - A Step in the Right Direction.
    N Engl J Med. 2020;383:2598-2600.
    PubMed    


  532. LEITER RE
    Reentry.
    N Engl J Med. 2020;383:e141.
    PubMed    


  533. BADEN LR, Solomon CG, Greene MF, D'Agostino RB, et al
    The FDA and the Importance of Trust.
    N Engl J Med. 2020;383:e148.
    PubMed    


  534. NIRULA A, Shen L, Skovronsky DM
    Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. Reply.
    N Engl J Med. 2020;384.
    PubMed    


  535. CASADEVALL A, Joyner MJ, Pirofski LA
    Neutralizing Antibody LY-CoV555 for Outpatient Covid-19.
    N Engl J Med. 2020;384.
    PubMed    


  536. FOPPIANO PALACIOS C, Travassos MA
    Vaccinating Detained Migrants against SARS-CoV-2 - Preventing Another Tragedy.
    N Engl J Med. 2020 Dec 30. doi: 10.1056/NEJMpv2035416.
    PubMed    


  537. BAROCAS JA
    Business Not as Usual - Covid-19 Vaccination in Persons with Substance Use Disorders.
    N Engl J Med. 2020 Dec 30. doi: 10.1056/NEJMpv2035709.
    PubMed    


  538. BADEN LR, El Sahly HM, Essink B, Kotloff K, et al
    Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
    N Engl J Med. 2020 Dec 30. doi: 10.1056/NEJMoa2035389.
    PubMed     Abstract available


  539. LEE MH, Perl DP, Nair G, Li W, et al
    Microvascular Injury in the Brains of Patients with Covid-19.
    N Engl J Med. 2020 Dec 30. doi: 10.1056/NEJMc2033369.
    PubMed    


  540. HAYNES BF
    A New Vaccine to Battle Covid-19.
    N Engl J Med. 2020 Dec 30. doi: 10.1056/NEJMe2035557.
    PubMed    


  541. CASTELLS MC, Phillips EJ
    Maintaining Safety with SARS-CoV-2 Vaccines.
    N Engl J Med. 2020 Dec 30. doi: 10.1056/NEJMra2035343.
    PubMed    


  542. HELLER HM, Gonzalez RG, Edlow BL, Ard KL, et al
    Case 40-2020: A 24-Year-Old Man with Headache and Covid-19.
    N Engl J Med. 2020;383:2572-2580.
    PubMed    


  543. MAITRA A
    Holding Up.
    N Engl J Med. 2020;383:2498-2499.
    PubMed    


  544. RITTENBERG E
    Sewing Masks - Resilience in the Face of Covid.
    N Engl J Med. 2020;383:2497-2498.
    PubMed    


  545. TAMBYRAJA AL
    New Order, New Hope.
    N Engl J Med. 2020;383:2495-2496.
    PubMed    


  546. LUMLEY SF, O'Donnell D, Stoesser NE, Matthews PC, et al
    Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.
    N Engl J Med. 2020 Dec 23. doi: 10.1056/NEJMoa2034545.
    PubMed     Abstract available


  547. STONE JH, Horick NK, Healy BC
    Tocilizumab in Covid-19. Reply.
    N Engl J Med. 2020;384.
    PubMed    


  548. LEAF DE, Gupta S, Wang W
    Tocilizumab in Covid-19.
    N Engl J Med. 2020;384.
    PubMed    


  549. LUNDGREN JD, Grund B, Barkauskas CE, Holland TL, et al
    A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.
    N Engl J Med. 2020 Dec 22. doi: 10.1056/NEJMoa2033130.
    PubMed     Abstract available


  550. CHASTAIN DB, Henao-Martinez AF, Young HN
    Racial Disproportionality in Covid Clinical Trials. Reply.
    N Engl J Med. 2020;383:2488-2490.
    PubMed    


  551. TOMASHEK KM, Mehta AK, Hynes NA
    Racial Disproportionality in Covid Clinical Trials.
    N Engl J Med. 2020;383:2487-2488.
    PubMed    


  552. GOLDMAN JD, Osinusi A, Marty FM
    Racial Disproportionality in Covid Clinical Trials.
    N Engl J Med. 2020;383:2486-2487.
    PubMed    


  553. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Covid-19 Vaccine Fundamentals.
    N Engl J Med. 2020;383:e146.
    PubMed    


  554. HUNTER DJ
    Trying to "Protect the NHS" in the United Kingdom.
    N Engl J Med. 2020;383:e136.
    PubMed    


  555. SALAMA C, Han J, Yau L, Reiss WG, et al
    Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.
    N Engl J Med. 2020 Dec 17. doi: 10.1056/NEJMoa2030340.
    PubMed     Abstract available


  556. WEINREICH DM, Sivapalasingam S, Norton T, Ali S, et al
    REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
    N Engl J Med. 2020 Dec 17. doi: 10.1056/NEJMoa2035002.
    PubMed     Abstract available


  557. BARIC RS
    Emergence of a Highly Fit SARS-CoV-2 Variant.
    N Engl J Med. 2020 Dec 16. doi: 10.1056/NEJMcibr2032888.
    PubMed    


  558. KALIL AC, Patterson TF, Mehta AK, Tomashek KM, et al
    Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
    N Engl J Med. 2020 Dec 11. doi: 10.1056/NEJMoa2031994.
    PubMed     Abstract available


  559. RUBIN EJ, Baden LR, Barocas JA, Morrissey S, et al
    Audio Interview: SARS-CoV-2 Vaccination and Vulnerable Populations.
    N Engl J Med. 2020;383:e143.
    PubMed    


  560. HUANG E, Jordan SC
    Tocilizumab for Covid-19 - The Ongoing Search for Effective Therapies.
    N Engl J Med. 2020;383:2387-2388.
    PubMed    


  561. LEICK MB
    Telephone.
    N Engl J Med. 2020;383:2304-2305.
    PubMed    


  562. POLACK FP, Thomas SJ, Kitchin N, Absalon J, et al
    Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
    N Engl J Med. 2020 Dec 10. doi: 10.1056/NEJMoa2034577.
    PubMed     Abstract available


  563. RUBIN EJ, Longo DL
    SARS-CoV-2 Vaccination - An Ounce (Actually, Much Less) of Prevention.
    N Engl J Med. 2020 Dec 10. doi: 10.1056/NEJMe2034717.
    PubMed    


  564. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Caring for Hospitalized Patients with Covid-19.
    N Engl J Med. 2020;383:e140.
    PubMed    


  565. FAJGENBAUM DC, June CH
    Cytokine Storm.
    N Engl J Med. 2020;383:2255-2273.
    PubMed    


  566. LAHEY T
    The Bottom of the Health Care Rationing Iceberg.
    N Engl J Med. 2020;383:2200-2201.
    PubMed    


  567. XING Y, Wong GWK, Ni W, Hu X, et al
    Rapid Response to an Outbreak in Qingdao, China.
    N Engl J Med. 2020;383:e129.
    PubMed    


  568. WIDGE AT, Rouphael NG, Jackson LA, Anderson EJ, et al
    Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
    N Engl J Med. 2020 Dec 3. doi: 10.1056/NEJMc2032195.
    PubMed    


  569. CAVALCANTI AB, Berwanger O, Zampieri FG
    Hydroxychloroquine with or without Azithromycin in Covid-19. Reply.
    N Engl J Med. 2020;383.
    PubMed    


  570. CHOUDHARY R, Bohra GK, Kumar D
    Hydroxychloroquine with or without Azithromycin in Covid-19.
    N Engl J Med. 2020;383.
    PubMed    


  571. KEANE MJ
    Hydroxychloroquine with or without Azithromycin in Covid-19.
    N Engl J Med. 2020;383.
    PubMed    


  572. PAN H, Peto R, Henao-Restrepo AM, Preziosi MP, et al
    Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
    N Engl J Med. 2020 Dec 2. doi: 10.1056/NEJMoa2023184.
    PubMed     Abstract available


  573. AYDILLO T, Gonzalez-Reiche AS, Aslam S, van de Guchte A, et al
    Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer.
    N Engl J Med. 2020 Dec 1. doi: 10.1056/NEJMc2031670.
    PubMed    


    November 2020
  574. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: New Studies of Covid-19 Transmission.
    N Engl J Med. 2020;383:e138.
    PubMed    


  575. KATZ DH, Wilson JG, Gerszten RE
    Mining a GWAS of Severe Covid-19.
    N Engl J Med. 2020;383.
    PubMed    


  576. KARIM M, Ghoussaini M, Dunham I
    Mining a GWAS of Severe Covid-19.
    N Engl J Med. 2020;383.
    PubMed    


  577. KENNEDY BS, Richeson RP, Houde AJ
    Risk Factors for SARS-CoV-2 in a Statewide Correctional System.
    N Engl J Med. 2020 Nov 24. doi: 10.1056/NEJMc2029354.
    PubMed    


  578. MITJA O, Corbacho-Monne M, Ubals M, Alemany A, et al
    A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.
    N Engl J Med. 2020 Nov 24. doi: 10.1056/NEJMoa2021801.
    PubMed     Abstract available


  579. SIMONOVICH VA, Burgos Pratx LD, Scibona P, Beruto MV, et al
    A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.
    N Engl J Med. 2020 Nov 24. doi: 10.1056/NEJMoa2031304.
    PubMed     Abstract available


  580. MANZANO GS, Woods JK, Amato AA
    Covid-19-Associated Myopathy Caused by Type I Interferonopathy.
    N Engl J Med. 2020 Nov 20. doi: 10.1056/NEJMc2031085.
    PubMed    


  581. RUBIN EJ, Baden LR, Haug CJ, Morrissey S, et al
    Audio Interview: Covid-19 in Europe and New Information on Vaccines.
    N Engl J Med. 2020;383:e134.
    PubMed    


  582. MALINA S, Warbelow S, Radix AE
    Two Steps Back - Rescinding Transgender Health Protections in Risky Times.
    N Engl J Med. 2020;383:e116.
    PubMed    


  583. RUBIN EJ, Baden LR, Woodcock J, Morrissey S, et al
    Audio Interview: An Update from Operation Warp Speed.
    N Engl J Med. 2020;383:e127.
    PubMed    


  584. CHOI B, Choudhary MC, Regan J, Sparks JA, et al
    Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host.
    N Engl J Med. 2020 Nov 11. doi: 10.1056/NEJMc2031364.
    PubMed    


  585. MICHAEL NL
    SARS-CoV-2 in the U.S. Military - Lessons for Civil Society.
    N Engl J Med. 2020 Nov 11. doi: 10.1056/NEJMe2032179.
    PubMed    


  586. LETIZIA AG, Ramos I, Obla A, Goforth C, et al
    SARS-CoV-2 Transmission among Marine Recruits during Quarantine.
    N Engl J Med. 2020 Nov 11. doi: 10.1056/NEJMoa2029717.
    PubMed     Abstract available


  587. KASPER MR, Geibe JR, Sears CL, Riegodedios AJ, et al
    An Outbreak of Covid-19 on an Aircraft Carrier.
    N Engl J Med. 2020 Nov 11. doi: 10.1056/NEJMoa2019375.
    PubMed     Abstract available


  588. DOLIN R, Hirsch MS
    Remdesivir - An Important First Step.
    N Engl J Med. 2020;383:1886-1887.
    PubMed    


  589. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: What the U.S. Response to Covid-19 Looks Like Today.
    N Engl J Med. 2020;383:e123.
    PubMed    


  590. MATIAS WR, Vaidya A, Brigl M, Bebell LM, et al
    A Patient with Fever and Dyspnea.
    N Engl J Med. 2020;383:e111.
    PubMed    


  591. GUDBJARTSSON DF, Stefansson K
    Early Spread of SARS-CoV-2 in the Icelandic Population. Reply.
    N Engl J Med. 2020;383.
    PubMed    


  592. COWIE BC, MacLachlan JH
    Early Spread of SARS-CoV-2 in the Icelandic Population.
    N Engl J Med. 2020;383.
    PubMed    


    October 2020
  593. LEVIN M
    Multisystem Inflammatory Syndrome in Children in the United States. Reply.
    N Engl J Med. 2020;383:1795-1796.
    PubMed    


  594. FELDSTEIN LR, Rose EB, Randolph AG
    Multisystem Inflammatory Syndrome in Children in the United States. Reply.
    N Engl J Med. 2020;383:1794-1795.
    PubMed    


  595. ARDITI M, Bahar I
    Multisystem Inflammatory Syndrome in Children in the United States.
    N Engl J Med. 2020;383:1794.
    PubMed    


  596. ALTER G, Seder R
    The Power of Antibody-Based Surveillance.
    N Engl J Med. 2020;383:1782-1784.
    PubMed    


  597. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: A New Monoclonal Antibody for Covid-19.
    N Engl J Med. 2020;383:e117.
    PubMed    


  598. WU K, Smith CR, Lembcke BT, Ferreira TBD, et al
    Elective Surgery during the Covid-19 Pandemic.
    N Engl J Med. 2020;383:1787-1790.
    PubMed    


  599. BLENDON RJ, Benson JM
    Implications of the 2020 Election for U.S. Health Policy.
    N Engl J Med. 2020;383:e105.
    PubMed    


  600. CAHAN EM, Levine LB, Chin WW
    The Human Touch - Addressing Health Care's Workforce Problem amid the Pandemic.
    N Engl J Med. 2020;383:e102.
    PubMed    


  601. DEFOREST A
    The New Stability.
    N Engl J Med. 2020;383:1708-1709.
    PubMed    


  602. HALABI S, Heinrich A, Omer SB
    No-Fault Compensation for Vaccine Injury - The Other Side of Equitable Access to Covid-19 Vaccines.
    N Engl J Med. 2020 Oct 28. doi: 10.1056/NEJMp2030600.
    PubMed    


  603. CHEN P, Nirula A, Heller B, Gottlieb RL, et al
    SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.
    N Engl J Med. 2020 Oct 28. doi: 10.1056/NEJMoa2029849.
    PubMed     Abstract available


  604. REYNOLDS HR, Adhikari S, Iturrate E
    RAAS Inhibitors and Risk of Covid-19. Reply.
    N Engl J Med. 2020;383.
    PubMed    


  605. MANCIA G, Rea F, Corrao G
    RAAS Inhibitors and Risk of Covid-19. Reply.
    N Engl J Med. 2020;383.
    PubMed    


  606. STRAUSS MH, Hall AS, Lavie CJ
    RAAS Inhibitors and Risk of Covid-19.
    N Engl J Med. 2020;383.
    PubMed    


  607. ISLAM N, Khunti K, Chowell G
    RAAS Inhibitors and Risk of Covid-19.
    N Engl J Med. 2020;383.
    PubMed    


  608. SRIRAM K, Loomba R, Insel PA
    RAAS Inhibitors and Risk of Covid-19.
    N Engl J Med. 2020;383.
    PubMed    


  609. ANGELI F, Verdecchia P, Reboldi G
    RAAS Inhibitors and Risk of Covid-19.
    N Engl J Med. 2020;383.
    PubMed    


  610. GANDHI M, Rutherford GW
    Facial Masking for Covid-19. Reply.
    N Engl J Med. 2020;383.
    PubMed    


  611. BROSSEAU LM, Roy CJ, Osterholm MT
    Facial Masking for Covid-19.
    N Engl J Med. 2020;383.
    PubMed    


  612. RASMUSSEN AL, Escandon K, Popescu SV
    Facial Masking for Covid-19.
    N Engl J Med. 2020;383.
    PubMed    


  613. PLATTON S, Bowles L, Pasi KJ
    Lupus Anticoagulant in Patients with Covid-19. Reply.
    N Engl J Med. 2020;383.
    PubMed    


  614. GOODING R, Myers B, Salta S
    Lupus Anticoagulant in Patients with Covid-19.
    N Engl J Med. 2020;383.
    PubMed    


  615. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Tocilizumab and Covid-19.
    N Engl J Med. 2020;383:e114.
    PubMed    


  616. CHOWDHURY JF, Moores LK, Connors JM
    Anticoagulation in Hospitalized Patients with Covid-19.
    N Engl J Med. 2020;383:1675-1678.
    PubMed    


  617. ROSENBAUM L
    Tribal Truce - How Can We Bridge the Partisan Divide and Conquer Covid?
    N Engl J Med. 2020;383:1682-1685.
    PubMed    


  618. WILENSKY GR
    Policy Lessons from Our Covid Experience.
    N Engl J Med. 2020;383:e96.
    PubMed    


  619. AGARWAL SD, Sommers BD
    Insurance Coverage after Job Loss - The Importance of the ACA during the Covid-Associated Recession.
    N Engl J Med. 2020;383:1603-1606.
    PubMed    


  620. BELOT A, Levy-Bruhl D
    Multisystem Inflammatory Syndrome in Children in the United States.
    N Engl J Med. 2020;383.
    PubMed    


  621. STRASSLE C, Jardas E, Ochoa J, Berkman BE, et al
    Covid-19 Vaccine Trials and Incarcerated People - The Ethics of Inclusion.
    N Engl J Med. 2020 Oct 21. doi: 10.1056/NEJMp2025955.
    PubMed    


  622. STONE JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, et al
    Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.
    N Engl J Med. 2020 Oct 21. doi: 10.1056/NEJMoa2028836.
    PubMed     Abstract available


  623. RAFIEI Y, Mello MM
    The Missing Piece - SARS-CoV-2 Testing and School Reopening.
    N Engl J Med. 2020 Oct 21. doi: 10.1056/NEJMp2028209.
    PubMed    


  624. KRAUSE PR, Gruber MF
    Emergency Use Authorization of Covid Vaccines - Safety and Efficacy Follow-up Considerations.
    N Engl J Med. 2020 Oct 16. doi: 10.1056/NEJMp2031373.
    PubMed    


  625. WARREN RC, Forrow L, Hodge DA Sr, Truog RD, et al
    Trustworthiness before Trust - Covid-19 Vaccine Trials and the Black Community.
    N Engl J Med. 2020 Oct 16. doi: 10.1056/NEJMp2030033.
    PubMed    


  626. KASER A
    Genetic Risk of Severe Covid-19.
    N Engl J Med. 2020;383:1590-1591.
    PubMed    


  627. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Vaccinology and Covid-19.
    N Engl J Med. 2020;383:e109.
    PubMed    


  628. GLIED S
    Health Policy in a Biden Administration.
    N Engl J Med. 2020;383:1501-1503.
    PubMed    


  629. WALSH EE, Frenck RW Jr, Falsey AR, Kitchin N, et al
    Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
    N Engl J Med. 2020 Oct 14. doi: 10.1056/NEJMoa2027906.
    PubMed     Abstract available


  630. SHAPIRO J, McDonald TB
    Supporting Clinicians during Covid-19 and Beyond - Learning from Past Failures and Envisioning New Strategies.
    N Engl J Med. 2020 Oct 14. doi: 10.1056/NEJMp2024834.
    PubMed    


  631. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Covid-19 and the President.
    N Engl J Med. 2020;383:e104.
    PubMed    



  632. Dying in a Leadership Vacuum.
    N Engl J Med. 2020;383:1479-1480.
    PubMed    


  633. HORBY P, Mafham M, Linsell L, Bell JL, et al
    Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
    N Engl J Med. 2020 Oct 8. doi: 10.1056/NEJMoa2022926.
    PubMed     Abstract available


  634. CELUM C, Barnabas R, Cohen MS, Collier A, et al
    Covid-19, Ebola, and HIV - Leveraging Lessons to Maximize Impact.
    N Engl J Med. 2020 Oct 7. doi: 10.1056/NEJMp2022269.
    PubMed    


  635. PAGE KR, Flores-Miller A
    Lessons We've Learned - Covid-19 and the Undocumented Latinx Community.
    N Engl J Med. 2020 Oct 7. doi: 10.1056/NEJMp2024897.
    PubMed    


  636. ROSENQUIST JN
    The Stress of Bayesian Medicine - Uncomfortable Uncertainty in the Face of Covid-19.
    N Engl J Med. 2020 Oct 7. doi: 10.1056/NEJMp2018857.
    PubMed    


  637. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Covid-19 Testing and the Individual Physician.
    N Engl J Med. 2020;383:e99.
    PubMed    


  638. HATA SR
    The Ritual of the Table.
    N Engl J Med. 2020;383:1301-1303.
    PubMed    


    September 2020
  639. RASMUSSEN SA, Lyerly AD, Jamieson DJ
    Delaying Pregnancy during a Public Health Crisis - Examining Public Health Recommendations for Covid-19 and Beyond.
    N Engl J Med. 2020 Sep 30. doi: 10.1056/NEJMp2027940.
    PubMed    


  640. MINA MJ, Parker R, Larremore DB
    Rethinking Covid-19 Test Sensitivity - A Strategy for Containment.
    N Engl J Med. 2020 Sep 30. doi: 10.1056/NEJMp2025631.
    PubMed    


  641. ANDERSON EJ, Rouphael NG, Widge AT, Jackson LA, et al
    Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
    N Engl J Med. 2020 Sep 29. doi: 10.1056/NEJMoa2028436.
    PubMed     Abstract available


  642. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Eight Months of Action and Inaction against Covid-19.
    N Engl J Med. 2020;383:e95.
    PubMed    


  643. CHRISTIE A, Neatherlin JC, Nichol ST, Beach M, et al
    Ebola Response Priorities in the Time of Covid-19.
    N Engl J Med. 2020;383:1202-1204.
    PubMed    


  644. CUNEO CN, Janeway H
    From Icebox to Tinderbox - A View from the Southern Border.
    N Engl J Med. 2020;383:e81.
    PubMed    


  645. YANG OO, Ibarrondo FJ
    Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. Reply.
    N Engl J Med. 2020;383.
    PubMed    


  646. KUTSUNA S, Asai Y, Matsunaga A
    Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19.
    N Engl J Med. 2020;383.
    PubMed    


  647. TERPOS E, Mentis A, Dimopoulos MA
    Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19.
    N Engl J Med. 2020;383.
    PubMed    


  648. BOLKE E, Matuschek C, Fischer JC
    Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19.
    N Engl J Med. 2020;383.
    PubMed    


  649. SCHWARTZ JL
    Evaluating and Deploying Covid-19 Vaccines - The Importance of Transparency, Scientific Integrity, and Public Trust.
    N Engl J Med. 2020 Sep 23. doi: 10.1056/NEJMp2026393.
    PubMed    


  650. PERETZ PJ, Islam N, Matiz LA
    Community Health Workers and Covid-19 - Addressing Social Determinants of Health in Times of Crisis and Beyond.
    N Engl J Med. 2020 Sep 23. doi: 10.1056/NEJMp2022641.
    PubMed    


  651. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Operation Warp Speed and Covid-19 Therapeutics.
    N Engl J Med. 2020;383:e92.
    PubMed    


  652. FISHMAN JA, Roberts MB, Zhang EW, Kumar D, et al
    Case 29-2020: A 66-Year-Old Man with Fever and Shortness of Breath after Liver Transplantation.
    N Engl J Med. 2020;383:1168-1180.
    PubMed    


  653. JOUNG J, Ladha A, Saito M, Kim NG, et al
    Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing.
    N Engl J Med. 2020 Sep 16. doi: 10.1056/NEJMc2026172.
    PubMed    


  654. EVANS ML, Lindauer M, Farrell ME
    A Pandemic within a Pandemic - Intimate Partner Violence during Covid-19.
    N Engl J Med. 2020 Sep 16. doi: 10.1056/NEJMp2024046.
    PubMed    


  655. AVORN J, Kesselheim AS
    Up Is Down - Pharmaceutical Industry Caution vs. Federal Acceleration of Covid-19 Vaccine Approval.
    N Engl J Med. 2020 Sep 15. doi: 10.1056/NEJMp2029479.
    PubMed    


  656. SLAOUI M, Greene SE, Woodcock J
    Bridging the Gap at Warp Speed - Delivering Options for Preventing and Treating Covid-19.
    N Engl J Med. 2020 Sep 15. doi: 10.1056/NEJMp2028535.
    PubMed    


  657. EVANS MK
    Health Equity - Are We Finally on the Edge of a New Frontier?
    N Engl J Med. 2020;383:997-999.
    PubMed    


  658. GOLDHAMER MEJ, Pusic MV, Co JPT, Weinstein DF, et al
    Can Covid Catalyze an Educational Transformation? Competency-Based Advancement in a Crisis.
    N Engl J Med. 2020;383:1003-1005.
    PubMed    


  659. SHUREN J, Stenzel T
    Covid-19 Molecular Diagnostic Testing - Lessons Learned.
    N Engl J Med. 2020 Sep 9. doi: 10.1056/NEJMp2023830.
    PubMed    


  660. GANDHI M, Rutherford GW
    Facial Masking for Covid-19 - Potential for "Variolation" as We Await a Vaccine.
    N Engl J Med. 2020 Sep 8. doi: 10.1056/NEJMp2026913.
    PubMed    


  661. BLOOM BR, Nowak GJ, Orenstein W
    "When Will We Have a Vaccine?" - Understanding Questions and Answers about Covid-19 Vaccination.
    N Engl J Med. 2020 Sep 8. doi: 10.1056/NEJMp2025331.
    PubMed    


  662. KEECH C, Albert G, Cho I, Robertson A, et al
    Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
    N Engl J Med. 2020 Sep 2. doi: 10.1056/NEJMoa2026920.
    PubMed     Abstract available


  663. GUDBJARTSSON DF, Norddahl GL, Melsted P, Gunnarsdottir K, et al
    Humoral Immune Response to SARS-CoV-2 in Iceland.
    N Engl J Med. 2020 Sep 1. doi: 10.1056/NEJMoa2026116.
    PubMed     Abstract available


    August 2020
  664. WYLLIE AL, Fournier J, Casanovas-Massana A, Campbell M, et al
    Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2.
    N Engl J Med. 2020 Aug 28. doi: 10.1056/NEJMc2016359.
    PubMed    


  665. SLAOUI M, Hepburn M
    Developing Safe and Effective Covid Vaccines - Operation Warp Speed's Strategy and Approach.
    N Engl J Med. 2020 Aug 26. doi: 10.1056/NEJMp2027405.
    PubMed    


  666. HORN DM, Haas JS
    Covid-19 and the Mandate to Redefine Preventive Care.
    N Engl J Med. 2020 Aug 12. doi: 10.1056/NEJMp2018749.
    PubMed    


  667. STUDDERT DM, Hall MA, Mello MM
    Partitioning the Curve - Interstate Travel Restrictions During the Covid-19 Pandemic.
    N Engl J Med. 2020 Aug 5. doi: 10.1056/NEJMp2024274.
    PubMed    


    July 2020
  668. CORBETT KS, Flynn B, Foulds KE, Francica JR, et al
    Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.
    N Engl J Med. 2020 Jul 28. doi: 10.1056/NEJMoa2024671.
    PubMed     Abstract available


  669. CAVALCANTI AB, Zampieri FG, Rosa RG, Azevedo LCP, et al
    Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
    N Engl J Med. 2020 Jul 23. doi: 10.1056/NEJMoa2019014.
    PubMed     Abstract available


  670. BERKOWITZ SA, Cene CW, Chatterjee A
    Covid-19 and Health Equity - Time to Think Big.
    N Engl J Med. 2020 Jul 22. doi: 10.1056/NEJMp2021209.
    PubMed    


  671. EGEDE LE, Walker RJ
    Structural Racism, Social Risk Factors, and Covid-19 - A Dangerous Convergence for Black Americans.
    N Engl J Med. 2020 Jul 22. doi: 10.1056/NEJMp2023616.
    PubMed    


  672. BLUMENTHAL D, Fowler EJ, Abrams M, Collins SR, et al
    Covid-19 - Implications for the Health Care System.
    N Engl J Med. 2020 Jul 22. doi: 10.1056/NEJMsb2021088.
    PubMed    


  673. HORBY P, Lim WS, Emberson JR, Mafham M, et al
    Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report.
    N Engl J Med. 2020 Jul 17. doi: 10.1056/NEJMoa2021436.
    PubMed     Abstract available


  674. NORTH CM, Dougan ML, Sacks CA
    Improving Clinical Trial Enrollment - In the Covid-19 Era and Beyond.
    N Engl J Med. 2020 Jul 15. doi: 10.1056/NEJMp2019989.
    PubMed    


  675. JACKSON LA, Anderson EJ, Rouphael NG, Roberts PC, et al
    An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.
    N Engl J Med. 2020 Jul 14. doi: 10.1056/NEJMoa2022483.
    PubMed     Abstract available


  676. HEATON PM
    The Covid-19 Vaccine-Development Multiverse.
    N Engl J Med. 2020 Jul 14. doi: 10.1056/NEJMe2025111.
    PubMed    


    June 2020
  677. MELLO MM, Silverman RD, Omer SB
    Ensuring Uptake of Vaccines against SARS-CoV-2.
    N Engl J Med. 2020 Jun 26. doi: 10.1056/NEJMp2020926.
    PubMed    


  678. ELLINGHAUS D, Degenhardt F, Bujanda L, Buti M, et al
    Genomewide Association Study of Severe Covid-19 with Respiratory Failure.
    N Engl J Med. 2020 Jun 17. doi: 10.1056/NEJMoa2020283.
    PubMed     Abstract available


    May 2020
  679. GOLDMAN JD, Lye DCB, Hui DS, Marks KM, et al
    Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
    N Engl J Med. 2020 May 27. doi: 10.1056/NEJMoa2015301.
    PubMed     Abstract available


  680. BEIGEL JH, Tomashek KM, Dodd LE, Mehta AK, et al
    Remdesivir for the Treatment of Covid-19 - Preliminary Report.
    N Engl J Med. 2020 May 22. doi: 10.1056/NEJMoa2007764.
    PubMed     Abstract available


  681. BERLIN DA, Gulick RM, Martinez FJ
    Severe Covid-19.
    N Engl J Med. 2020 May 15. doi: 10.1056/NEJMcp2009575.
    PubMed    


    April 2020
  682. GANDHI RT, Lynch JB, Del Rio C
    Mild or Moderate Covid-19.
    N Engl J Med. 2020 Apr 24. doi: 10.1056/NEJMcp2009249.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: